INDEX TO VOLUME 19

AUTHOR INDEX

(S = supplement; L = letter to the Editors; P = proceedings)

ABERNETHY, D. R., TODD, E. L. & SCHWARTZ, J. B. Caffeine disposition in obesity, 61

ABILA, B., WILSON, J. F., MARSHALL, R. W. & RICHENS, A. The tremorolytic action of β-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by β-adrenoceptors located in a deep peripheral compartment, 369

ACHARI, R., HULSE, J. D., DRISSEL, D. & MATIER, W. L. Pharmacokinetics of flestolol in man: preliminary data, 691

ADAMS, P. C., SLOAN, P., MORLEY, A. R. & HOLT, D.W. Neutrophil inclusions in amiodarone-treated patients, 523P

ADITHAN, C. *see* RAY, K.

ADJEPON-YAMOAH, K. K., WOOLHOUSE, N. M., OFORI-ADJEI, D. & NORTEY, L. N. Chloroquine decreases oral caecal transit time, 425

ADJEPON-YAMOAH, K. K. *see* WILLIAMS, F. M.

ADVENIER, C. *see* VAROQUAUX, O.

AELLIG, W. H. *see* CARRUTHERS, S. G.

AHMAD, D. *see* PEARSON, M. G.

AICHELE, G. *see* GLEITER, C. H.

AJAYI, A. A., CAMPBELL, B. C., GILBERT, L., SUMNER, D. J., RUBIN, P. C. & REID, J. L. The actions of naloxone on the cardiovascular and autonomic effects of captopril in man, 262P

AJAYI, A. A., CAMPBELL, B. C., MEREDITH, P. A., KELMAN, A. W. & REID, J. L. The effect of captopril on the reflex control of heart rate: possible mechanisms, 17

AJAYI, A. A. *see* HOCKINGS, N.

AL-KHAWAJA, I. *see* CARUANA, M. P.

AL-SAFI, S. A. *see* SZAWLOWSKI, P. W. S.

ALBERTI, K. G. M. M. *see* FERNER, R. E.

ALEXANDER, O. F. *see* GRAHAM, D. J. M.

ALI, N. A., MARSHALL, R. W., ALLEN, E. M., GRAHAM, D. F. & RICHENS, A. Comparison of the effects of therapeutic doses of meptazinol and a dextropropoxyphene/paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements, 631

ALLEN, E. *see* ELBAHIE, N.

ALLEN, E. M. *see* ALI, N. A.

ALLEN, E. M. *see* ELBAHIE, N.

ALPS, B. J., CALDER, C. & WILSON, A. Nicardipine in models of myocardial infarction, 29S

ALTAMURA, A. C. & MAURI, M. Plasma concentrations, information and therapy adherence during long-term treatment with antidepressants, 714

ANDRIEU, J. *see* VAROQUAUX, O.

ANGELO, H. R. *see* BONDE, J.

ANKIER, S. I. *see* SWIFT, C. G.

ANTONIN, K. H. *see* GLEITER, C. H.

ARNAUD, A. *see* BRUGUEROLLE, B.

ARNAUD, C. *see* BRUGUEROLLE, B.

ARONSON, J. K. *see* GREEN, A. R.

ARONSON, J. K. *see* RAPEPORT, W. G.

ARR, S. M., WOOLLARD, M. L., FAIRHURST, G., PIPPEN, C., RAO, S. K. & COOPER, W. D. Safety and efficacy of enalapril in essential hypertension in the elderly, 279P

ASANO, M. *see* TAKENAKA, T.

ASHBY, L. *see* COHEN, A. F.

ASHBY, L. *see* HAMILTON, M. J.

ASPLUND, J. Nicardipine hydrochloride in essential hypertension — a controlled study, 120S

AUSTEN, K. F. *see* LEWIS, R. A.

BARR, R. M. *see* KOBZA BLACK, A.

BABIKER, M. *see* DENNIS, M. J.

BACK, D. J. *see* CRAWFORD, P.

BACK, D. J. *see* EL-RAGHY, I.

BACK, D. J. *see* WINSTANLEY, P. A.

BACKHOUSE, G. *see* BENTLEY, D. P.

BALANT, L. P. *see* BERG, S. J.

BALFRE, K. *see* RICHARDSON, P. S.

BALL, S. G. *see* MANHEM, P. J. O.

BANKS, J. *see* EBDEN, P.

BAPNA, J. S. *see* RAY, K.

BARCHOWSKY, A. *see* ROUTLEDGE, P. A.

BARNES, N. C., ZAKRZEWSKI, J. T., PIPER, P. J. & COSTELLO, J. F. Reproducibility of histamine and leukotriene D_4 inhalation challenge in normal humans, 554P

BARNES, P. J. Clinical studies with calcium antagonists in asthma, 289S

BARNES, P. J. Peptides in asthma, 519P

BARROW, S. E. *see* HEAVEY, D. J.

BATEMAN, D. N. Studies on the pharmacological control of gastric emptying in man, 339

BATEMAN, D. N., RAWLINS, M. D. & SIMPSON, J. M. Epidemiology of acute dyskinetic-dystonic reactions to metoclopramide and prochlorperazine, 258P

BATEMAN, D. N. *see* BURGESS, P.

BATEMAN, D. N. *see* LEESER, J.

BATEMAN, D. N. *see* TAYLOR, W. B.

BATEMAN, D. N. *see* WEBB, D.

BATY, J. *see* DOW, R. J.

BATY, J. *see* ISLES, T. E.

BAX, N. D. S., TUCKER, G. T. & WOODS, H. F. A survey of the clinical use of lignocaine in coronary care units 1978–1984, 539P

BAX, N. D. S. *see* SANCHEZ-MARTINEZ, V.

BELLET, M. *see* FORETTE, F.

BENCIVELLI, V. *see* KERWIN, R. W.

BENNETT, P. N. *see* LEWIS, L. D.

BENTLEY, D. P., BACKHOUSE, G., HUTCHINGS, A., HADDON, R. L., SPRAGG, B. P. & ROUTLEDGE, P.

A. Investigation of patients with abnormal response to warfarin, 300P
BERDEAUX, A. *see* GIUDICELLI, J. F.
BERG, S. J., BALANT, L. P., CLARKE, I. & FAIRFAX, A. J. Slow release choline theophyllinate (Sabidal SR 270) in chronic asthma, 89L
BERRY, H. *see* STEVENS, J.
BERTILSSON, L. *see* NOIRDIN, C.
BIECK, P. R. *see* GLEITER, C. H.
BINNIE, C. D., VAN EMDE BOAS, W., LAND, G. S., MEIJER, J. W. A., OVERWEG, J. & VAN WIERINGEN, A. Preliminary single-dose studies of a potential new anti-epileptic drug, lamotrigine (BW430C) in epileptic patients, 285P
BIRKETT, D. J. *see* ROBSON, R. R.
BIRMINGHAM, A. T. *see* JEFFERSON, D.
BJORKMAN, S. Stereoselective disposition of indoprofen in surgical patients, 463
BLACK, D. J. *see* RIVIERE, J. H.
BLACK, J., VINCENC, K. & SALOME, C. Inhibition of methoxamine-induced bronchoconstriction by ipratropium bromide and disodium cromoglycate in asthmatic subjects, 41
BLACKIE, R. G. *see* KERR, D. J.
BLAIN, P. G., MUCKLOW, J. C., RAWLINS, M. D., ROBERTS, D. F., ROUTLEDGE, P. A. & SHAND, D. G. Determinants of plasma α_1-acid glycoprotein (AAG) concentrations in health, 500
BLAKE, D. *see* GEORGE, C. F.
BLOOM, B. *see* STEVENS, J.
BLYCHERT, L.-O. *see* NYBERG, G.
BOCHNER, F. *see* SOMOGYI, A.
BODTKER, S. *see* BONDE, J.
BOLLI, P. *see* HULTHEN, U. L.
BONDE, J., PEDERSEN, L. E., BODTKER, S., ANGELO, H. R., Svendsen, T. L. & KAMPMANN, J. P. The influence of age and smoking on the elimination of disopyramide, 453
BOOBIS, A. R. *see* CLARE KAHN, G.
BOOBIS, A. R. *see* SEDDON, T.
BOOTH, J. *see* KEMP, J.
BOSSUYT, A. M. *see* DUPONT, A. G.
BOUCHACOURT, P. *see* FORETTE, F.
BOUTAGY, J. S. *see* MORE, D. G.
BOUTHIER, J. *see* LEVENSON, J.
BOWLES, M. J., KHURMI, N. S., O'HARA, M. J. & RAFTERY, E. B. Nicardipine in chronic stable angina: objective assessment with computer-assisted exercise testing and ambulatory ST segment monitoring, 177S
BRADBROOK, I. D., GILLIES, H. C., MORRISON, P. J., ROBINSON, J., ROGERS, H. J. & SPECTOR, R. G. Effects of single and multiple doses of ketoconazole on adrenal function in normal subjects, 163
BRADSHAW, C. M. *see* LONGMORE, J.
BRAIN, S. *see* KOBZA BLACK, A.
BRAVERMAN, A. M., GHOSH, D., KAYE, C. M. & MITCHELL, P. The pharmacokinetics of ketoprofen in geriatric subjects given a single oral dose of a controlled release formulation, 298P
BRAY, C. *see* FANANAPAZIR, L.
BRECKENRIDGE, A. M. Human pharmacology, session summary — first international symposium on nicardipine, 103S
BRECKENRIDGE, A. M. *see* CHOONARA, I. A.
BRECKENRIDGE, A. M. *see* RIVIERE, J. H.
BRECKENRIDGE, A. M. *see* WINSTANLEY, P. A.
BREIMER, D. D. *see* TEUNISSEN, M. W. E.
BRILEY, M. *see* PUOZZO, C.
BRODIE, M. J. *see* CLARE KAHN, G.
BROOKS, P. M. *see* MEFFIN, P. J.
BRORS, O. & JACOBSON, S. pH lability in serum during equilibrium dialysis, 85
BROWN, D. C. *see* BROWN, M. J.
BROWN, J. *see* WORTH, D. P.
BROWN, M. J., STRUTHERS, A. D., BURKIN, J. M., DI SILVO, L. & BROWN, D. C. The physiological and pharmacological role of presynaptic α- and β-adrenoceptors in man, 649
BROWN, M. J. *see* QUIGLEY, C.
BROWN, R. C. *see* DAVIES, P. D. O.
BROWNE, P. D. *see* MEYRICK THOMAS, R.H.
BRUGUEROLLE, B., PHILIP-JOET, F., ARNAUD, C. & ARNAUD, A. Consequences of inflammatory processes on lignocaine protein binding during anaesthesia in fibreoptic bronchoscopy, 180L
BRUINING, G. J. *see* TEUNISSEN, M. W. E.
BUHLER, F. R. *see* HULTHEN, U. L.
BURGESS, P., HALL, R. I., BATEMAN, D. N. & JOHNSTON, I. D. A. Antipyrine clearance during total parental nutrition in man, 253P
BURKE, C. A. *see* YUEN, W. C.
BURLEIGH, D. E. & TROUT, S. J. Evidence against acetylcholine releasing action of cisapride in the human colon, 475
BURRIN, J. M. *see* BROWN, M. J.
BUSS, D. C. *see* EBDEN, P.
BUSS, D. C. *see* WATT, A. H.
BUSS, D. C. *see* WEBB, D.
BUTLER, R. C., GODDARD, D. H., HIGGENS, C. S., HOLLINGWORTH, P., PEASE, C. T., STODELL, M. A. & SCOTT, J. T. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis, 511
BYE, A. *see* COHEN, A. F.

CALDER, C. *see* ALPS, B. J.
CALDWELL, J. & HOTCHKISS, S. A. An h.p.l.c. assay for theophylline and its major metabolites in human urine, 545P
CAMERON, C. M. *see* CAMERON, H. A.
CAMERON, H. A., CAMERON, C. M. & RAMSAY, L. E. A double-blind, placebo-controlled study of the antianginal effect of ketanserin in patients receiving a β-adrenoceptor antagonist, 525P
CAMPBELL, B. C., KELMAN, A. W. & HILLIS, W. S. Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects, 55S
CAMPBELL, D. B., INGS, R. M. J. & GORDON, B. H. The effect of food on the availability of almitrine bismesylate, a new chemoreceptor agonist, 547P
CAMPBELL, I. A., EBEJER, M. J., HENDERSON, A. H., HIGGINS, D. A. & SINGH, H. Acute haemodynamic and neurohumoral effects of nifedipine at rest and on exercise in patients with chronic cor pulmonale, 248S
CAMPBELL, L. *see* MEREDITH, P.A.
CARLISLE, R. J. T., DUNDEE, J. W., HARPER, K. W. & COLLIER, P. S. Prolonged midazolam elimination half-life in a minority of patients, 534P
CARRUTHERS, S. G., PACHA, W. L. & AELLIG, W. H.

Contrasts between pindolol and propranolol concentration response relationships, 417
CARUANA, M. P., AL-KHAWAJA, I., ROYSTON, P. & RAFTERY, E. B. The effects of long-acting pinacidil on intra-arterial blood pressure, 140
CARVER, J. G. *see* RAPEPORT, W. G.
CHADWICK D. *see* CRAWFORD, P.
CHALLENOR, V. F., RENWICK, A. G., GRUCHY, B. S., WALLER, D. & GEORGE, C. F. The effects of food and posture on the pharmacokinetics of a novel formulation of nifedipine, 550P
CHALMERS, J. L. *see* GUAY, D. R. P.
CHAMBERLAIN, M. J. *see* PEARSON, M. G.
CHAMBERS, D. R. *see* OWEN, F.
CHAN, K., LAU, E. M. C. & SO, A. The use of narcotic analgesics in hospital practice in Hong Kong, 553P
CHAN, K., TSE, J., JENNINGS, F. & ORME, M. L'E. Pethidine disposition among healthy Caucasian, Chinese and Indian subjects, 531P
CHAN, M. K. *see* PUN, K. K.
CHAPPELL, C. G. *see* HEAVEY, D. J.
CHAPUT DE SAINTONGE, D. M. & KIRWAN, J. R. How can we discover which treatment responses are clinically important? 530P
CHARLIER, A. A. *see* ROUSSEAU, M. F.
CHERON, P. *see* ROUSSEAU, M. F.
CHIA, B. L. *see* OH, V. M. S.
CHIERCHIA, S. *see* KERWIN, R. W.
CHOLERTON, S. *see* CHOONARA, I. A.
CHOONARA, I. A., SCOTT, A. K., HAYNES, P. B., BRECKENRIDGE, A. M. & PARK, B. K. Vitamin K_1 metabolism in relation to pharmacodynamic response in anticoagulated patients, 265P
CHOONARA, I. A., SCOTT, A. K., HAYNES, B. P., CHOLERTON, S., BRECKENRIDGE, A. M. & PARK, B. K. Vitamin K_1 metabolism in relation to pharmacodynamic response in anticoagulated patients, 643
CHURCH, M. K. Adenosine as a mediator of asthma, 520P
CLARE KAHN, G., BOOBIS, A. R., BRODIE, M. J., TOVERUD, E.-L., MURRAY, S. & DAVIES, D. S. Phenacetin *O*-diethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? 67
CLARKE, I. *see* BERG, S. J.
CLARKE, P. *see* SWIFT, C. G.
CLARKE, R. J. S. *see* GIBSON, F. M.
CLELAND, G. F., SEMPLE, P. F., DARGIE, H. J., MCALPINE, H. M., BALL, S. G. & ROBERTSON, J. S. First dose hypotension with captopril and enalapril in heart failure, 263P
CLELAND, P. *see* CRAWFORD, P.
COHEN, A. F., ASHBY, L., CROWLEY, D., LAND, G. & PECK, A. W. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam, 619
COHEN, A. F., ASHBY, L., CROWLEY, D. & PECK, A. W. CNS effects in normal volunteers of phenytoin, diazepam and lamotrigine (BW430C), a new anticonvulsant, 286P
COHEN, A. F., FOWLE, A. S. E., LAND, G. S. & BYE, A. Pharmacokinetics in normal man of lamotrigine (BW430C), a new anticonvulsant, 286P
COHEN, A. F. *see* HAMILTON, M. J.
COLLIER, P. S. *see* CARLISLE, R. J. T.
COLLIER, P. S. *see* WILSON, C. M.
COLLISTE, P. *see* EDGER, B.
CONNELLY, D. M. *see* TABERNER, P. V.
COOK, S. K. *see* NORRIS, S. C.
COOPER, S. J. *see* OWEN, F.
COOPER, W. D., DOYLE, G., DONOHOE, J., LAHAR, M., LEDINGHAM, J., RAINE, A., MELNICK, S. C., UNSWORTH, J., VENKAT RAMAN, G., VANDENBURG, M. J. & WOOLLARD, M. L. Enalapril in the treatment of hypertension associated with impaired renal function, 280P
COOPER, W. D. *see* ARR, S. M.
COOPER, W. D. *see* KELLY, J.
COOPER, W. D. *see* VANDENBERG, M. J.
Cordonnier, P. *see* VAROQUAUX, O.
COSTELLO, J. F., DUNLOP, L. S. & GARDINER, P. J. Characteristics of prostaglandin induced cough in man, 355
COSTELLO, J. F. *see* BARNES, N. C.
COWEN, K. J. *see* MCGOURTY, J. C.
COWEN, P. J. *see* GREEN, A. R.
COWIE, A. *see* CRAWFORD, P.
CRAWFORD, P., CHADWICK, D. P., CLELAND, P., TJIA, J., COWIE, A., BACK, D. J. & ORME, M. L'E. Sodium valproate and oral contraceptive steroids, 288P
CROME, P. *see* DENNIS, M. J.
CRONIN, C. J., WALDEN, R. J., GRAHAM, B. R., SMITH, C. C. T. & PRICHARD, B. N. C. Does LI-32-468 exhibit selective β_2-adrenoceptor blocking action in hypertensive patients? 275P
CROTHERS, M. J. *see* WYNNE, H.
CROW, T. J. *see* FARMERY, S. M.
CROW, T. J. *see* OWEN, F.
CROWE, J. *see* O'BOYLE, C. A.
CROWLEY, D. *see* COHEN, A. F.
CROWLEY, D. *see* POSNER, J.
CULLING, W., SHERIDAN, D. J. & THOMAS, P. Systematic and coronary haemodynamic effects of α_1-adrenoceptor blockade in patients with coronary artery disease, 247P
CUMMING, A. D. *see* MACKAY, I. G.
CUNNINGMAN, D. *see* KERR, D. J.
CURRIE, W. J. C. *see* KELLY, J.
CZECH, T. & KORN, A. Intracranial effects of nicardipine, 67S
CZECHANOWSKI, B. *see* FRIEBEL, P.

DALRYMPLE, P. D. & NICHOLLS, P. J. Characterization of aminoglutethimide plasma protein binding in man, 295P
DANESHMEND, T. K. *see* LOWE, C. H.
DARRAGH, A. *see* GEORGE, C. F.
DAVIES, B. E. Displacement of bilirubin from cord serum by sulphadimethoxine, clavulanic acid in combination with either amoxycillin or ticarcillin, temocillin and cloxacillin, 345
DAVIES, D. S. *see* CLARE KAHN, G.
DAVIES, D. S. *see* SEDDON, T.
DAVIES, G. J. *see* KERWIN, R. W.
DAVIES, G. J. *see* VORA, J.
DAVIES, I. B. *see* GRIND, I. M.
DAVIES, P. D. O., BROWN, R. C. & WOODHEAD, J. S.

The effect of anti-tuberculous chemotherapy on vitamin D, and liver function, 303P
Davies, S. L. *see* Theodorou, A. E.
Dayer, P. *see* Osikowska-Evers, B. A.
De Bono, G. G. β_1-adrenoceptor selectivity and intrinsic sympathomimetic activity, 92L
De Jongh, B. M. *see* Teunissen, M. W. E.
De Schepper, J. *see* Van Hecken, A. M.
De Vries, J. *see* Friebel, P.
Debbas, N. M. G., Ings, R. M. J., Gordon, B. H., Richards, R. P., Jackson, S. H. D. & Turner, P. (+)-Fenfluramine: relative and absolute bioavailability of a solution compared to a capsule, 549P
Debbas, N. M. G. *see* Sowemimo-Coker, S. O.
Dejong, H. G. *see* Wilson, J. F.
Dennis, M. J., French, P. C., Crome, P., Babiker, M., Shillingford, J. & Hopkins, R. Pharmacokinetic profile of controlled release ketoprofen in elderly patients, 567
Deray, G. Captopril pharmacokinetics, 90L
Dickinson, R. *see* Kobza Black, A.
Dijkhuis, I. C. *see* Wilson, J. F.
Di Silvo, L. *see* Brown, M. J.
Disney, A. P. *see* Reece, P. A.
Doenicke, A. *see* Duka, Th.
Doll, J. *see* Varoquaux, O.
Dollery, C. T. *see* Heavey, D. J.
Donohoe, J. *see* Cooper, W. D.
Donohoe, J. *see* Kelly, J.
Dooley, T. *see* Szawlowski, P. W. S.
Dow, R. J., Baty, J. & Isles, T. E. The effect of nicardipine on glucose and drug-stimulated insulin secretion in normal volunteers, 75S
Dow, R. J. *see* Graham, D. J. M.
Dow, R. J. *see* Isles, T. E.
Doyle, M. C., George, A. J., Ravindran, A. V. & Philpott, R. M. A comparison of the dexamethasone suppression test (DST) with platelet [^{3}H]-clondine binding in dementia and depressive patients, 261P
Doyle, G. *see* Cooper, W. D.
Doyle, G. *see* Kelly, J.
Drissel, D. *see* Achari, R.
Ducreuzet, C. *see* Varoquaux, O.
Duka, Th., Hohe, M., Doenicke, A. & Matussek, N. Is a histaminergic mechanism involved in opiate stimulated growth hormone release? 283P
Dundee, J. W. *see* Carlisle, R. J. T.
Dundee, J. W. *see* Robinson, F. P.
Dundee, J. W. *see* Wilson, C. M.
Dunlop, L. S. *see* Costello, J. F.
Dupont, A. G., Vanderniepen, P., Bossuyt, A. M., Jonckheer, M. H. & Six, R. O. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function, 93
Duthie, H. L. *see* Taylor, B. A.
Dyas, J. *see* Evans, P. J.

Ebden, P., Banks, J., Peel, T., Buss, D. C., Routledge, P. A. & Spragg, B. P. The disposition of theophylline in blood in obstructive airway disease, 300P
Ebejer, M. J. *see* Campbell, I. A.
Edgar, B., Colliste, P., Haglund, K. & Regardh, C.-C. Pharmacokinetics of felodipine after an acute dose and after repeated administration, 249P
Edgar, B. *see* Elbahie, N.
Edgar, B. *see* Janzon, K.
Edgar, D. *see* Pinney, H.
Edouard, A. *see* Giudicelli, J. F.
Eichelbaum, M. *see* Osikowska-Evers, B. A.
Eisenhofer, D. G., Lambie, D. G. & Johnson, R. H. No effect of ethanol ingestion on β-adrenoceptor-mediated circulatory responses to isoprenaline in man, 684
El-Raghy, I., Back, D. J., Osman, F., Nafeh, M. A. & Orme, M. L'E. The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis, 313
Elbahie, N., Allen, E. M., Williams, J. & Routledge, P. A. The effect of activated charcoal on the absorption of mefenamic acid, 254P
Elbahie, N., Edgar, B., Allen, E., Hill, T. W. K., Johansson, L., Wilson, J. F. & Routledge, P. A. Food and the pharmacokinetics of felodipine, 299P
Elliott, H. L., Pasanisi, F. & Reid, J. L. Effects of nicardipine on aldosterone release and pressor mechanisms, 99S
Elliott, H. L. *see* Jones, C. R.
Elliott, H. L. *see* Meredith, P. A.
Elliott, H. L. *see* Vincent, J.
Evans, P. J., Walker, R. F., Peters, J. R., Dyas, J., Riad-Fahmy, D., Thomas, J. P., Rimmer, E., Tsanaclis, L. & Scanlon, M. F. Anticonvulsant therapy and cortisol elimination, 129
Ewen, J. M. *see* Swift, C. G.
Ewen, S. W. *see* Nyemitei-Addo, I.

Fairfax, A. J. *see* Berg, S. J.
Fairhurst, G. *see* Arr, S. M.
Fananapazir, L. & Bray, C. Comparison of oxyfedrine and atenolol in angina pectoris — a double-blind study, 405
Farmery, S. M., Crow, T. J., Owen, F. & Poulter, M. (^{125}I)vasoactive intestinal polypeptide binding to post-mortem brain samples from controls and schizophrenic patients, 260P
Fennerty, A. G., Scolding, N. J., Renowden, S. & Routledge, P. A. Guidelines for control of heparin therapy, 266P
Ferguson, J., Macdonald, K. J. S. & Kenicer, K. J. A. Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study, 639
Ferner, R. E., Alberti, K. G. M. M. & Rawlins, M. D. A glucose-clamp technique demonstrates increased β-cell glucose sensitivity after chronic tolbutamide therapy, 270P
Ferry, D. R., Goll, A., Rombusch, M. & Glossman, H. The molecular pharmacology and structural features of calcium channels, 233S
Fifield, R. *see* Webb, D.
Filaquier, C. *see* Puozzo, C.
Finch, M. B. & Johnston, G. D. The peripheral vascular effects of diltiazem — dose-response characteristics, 447
Finch, M. B. *see* Johnston, G. D.
Finch, M. J. *see* O'Connor, P. C.
Fish, R. G. *see* Yap, A. K. L.

FOLGERING, H. TH. M. *see* LAMMERS, J. W. J.
FORETTE, F., BELLET, M., HENRY, J. F., HERVY, M. P., POYARD-SALMERON, C., BOUCHACOURT, P. & GUERRET, M. Effects of nicardipine in elderly hypertensive patients, 125S
FORREST, J. A. H. *see* HOWDEN, C. W.
FOWLE, A. S. E. *see* COHEN, A. F.
FOWLER, P. *see* THOMAS, M.
FRAIS, M. A., SILKE, B., VERMA, S. P., REYNOLDS, G., HAFIZULH, M., KALRA, P., JACKSON, N. & TAYLOR, S. H. Comparative effects of intravenous disopyramide and flecainide in acute myocardial infarction, 522P
FRAIS, M. A. *see* JACKSON, N. C.
FRAIS, M. A. *see* SILKE, B.
FRAIS, M. A. *see* TAYLOR, S. H.
FRAIS, M. A. *see* VERMA, S. P.
FRASER, A. G., HENDERSON, A. H., LEWIS, M. J., MULLIGAN, I. P. & TIRLAPUR, V. G. Acute and chronic effects of enalapril during rest and exercise in congestive heart failure, 263P
FRASER, R. *see* MANHEM, P. J. O.
FREEDMAN, D. *see* GEORGHIADE, M.
FREEDMAN, D. *see* GRAHAM, D. J. M.
FREEDMAN, D. *see* SCHEIDT, S.
FREESTONE, S. *see* SILAS, J. H.
FRENCH, P. C. *see* DENNIS, M. J.
FRIEBEL, P., WALTER-SACK, I., UKENA, D., CZECHANOWSKI, B., DE VRIES, J. & WEBER, E. Influence of a single dose of cimetidine 800 mg and ranitidine 300 mg on oxidative drug transformation (antipyrine clearance), 446P

GAILLOT, J. *see* MATHESON, I.
GARDINER, P. J. *see* COSTELLO, J. F.
GELMAN, J. S. *see* PEPINE, C. J.
GEORGE, A. J. *see* DOYLE, M. C.
GEORGE, C. F., RENWICK, A. G., DARRAGH, A., BLAKE, D., HOSIE, J. & SCOTT, D. A comparison of the pharmacokinetics of isoxicam in young and elderly subjects: a multicentre study, 533P
GEORGE, C. F. *see* CHALLENOR, V. F.
GEORGE, C. F. *see* RENWICK, A. G.
GEORGE, C. F. *see* ROBERTS, A.
GEORGE, C. F. *see* STRONG, H. A.
GEORGHIADE, M., ST CLAIR, C., ST CLAIR, J., FREEDMAN, D. & SCHWEMER, G. Short- and long-term treatment of stable effort angina with nicardipine, a new calcium channel blocker: a double-blind, placebo-controlled, randomised, repeated crossover study, 195S
GEYSKES, G. G. *see* VAN SCHAIK, B. A. V.
GHOSH, D. *see* BRAVERMAN, A. M.
GIBSON, F. M. *see* LAVERY, G. G.
GILBERT, L. *see* AJAYI, A. A.
GILLIES, H. C. *see* BRADBROOK, I. D.
GIUDICELLI, J. F., BERDEAUX, A., EDOUARD, A. K., RICHER, C. & JACOLOT, D. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects, 211
GIUDICELLI, J. F. & RICHER, G. Captropril pharmacokinetics and biological and clinical effects, 91L
GLEITER, C. H., AICHELE, G., NILSSON, E., HENGEN, N., ANTONIN, K. H. & BIECK, P. R. Discovery of altered pharmacokinetics of CGP 15 210G in poor hydroxylators of debrisoquine during early drug development, 81
GLOSSMANN, H. *see* FERRY, D. R.
GOBERT, G. *see* VAROQUAUX, O.
GODDARD, D. H. *see* BUTLER, R. C.
GOLL, A. *see* FERRY, D. R.
GOODWIN, J. F. Closing comments – first international symposium on nicardipine, 208S
GOODWIN, J. F. Introduction to the first international symposium on nicardipine, 3S
GORDON, B. H. *see* CAMPBELL, D. B.
GORDON, B. H. *see* DEBBAS, N. M. G.
GOULD, S. *see* HOSIE, J.
GRAHAM, B. R. *see* CRONIN, C. J.
GRAHAM, D. F. *see* ALI, N. A.
GRAHAM, D. J. M., DOW, R. J., HALL, D. J., ALEXANDER, O. F., MROSZCZAK, E. J. & FREEDMAN, D. The metabolism and pharmacokinetics of nicardipine hydrochloride in man, 23S
GRAHAM, J. *see* KERR, D. J.
GRAHAME, G. R. *see* GUAY, D. R. P.
GRAHAME-SMITH, D. G. *see* RAPEPORT, W. G.
GRAINGER, S. L. *see* JONES, A. L.
GREAVES, M. W. *see* HEAVEY, D. J.
GREAVES, M. W. *see* KOBZA BLACK, A.
GREEN, A. R., ARONSON, J. K. & COWEN, P. J. The pharmacokinetics of L-tryptophan following its intravenous and oral administration, 317
GRIFFITH, R. L. *see* PETERSON, G. M.
GRIFFITHS, A. N. *see* MARSHALL, R. W.
GRIFFITHS, A. N. *see* TEDESCHI, G.
GRIND, I. M., DAVIES, I. B., SINCLAIR, A. J. & WARRINGTON, S. J. Plasma tyramine/noradrenaline concentrations and blood pressure response to oral tyramine: effect of MAO Type A inhibition, 266P
GROB, P. *see* LUMLEY, C. E.
GROSBUIS, S. *see* VAROQUAUX, O.
GRUCHY, B. S. *see* CHALLENOR, V. F.
GUAY, D. R. P., MEATHERALL, R. C., CHALMERS, J. L., GRAHAME, G. R. & HUDSON, R. J. Ranitidine does not alter pethidine disposition in man, 55
GUDGEON, A. *see* NIEVEL, J. G.
GUERRET, M. *see* FORETTE, F.

HABEDANK, W.-D. *see* WOODCOCK, B. G.
HACKETT, L. P. *see* KEMP, J.
HADDON, R. L. *see* BENTLEY, D. P.
HAFIZULLAH, M. *see* FRAIS, M. A.
HAFIZULLAH, M. *see* SILKE, B.
HAGLUND, K. *see* EDGER, B.
HALE, A. S. *see* THEODOROU, A. E.
HALL, D. J. *see* GRAHAM, D. J. M.
HALL, G. C. *see* LUMLEY, C. E.
HALL, R. I. *see* BURGESS, P.
HALLIDAY, N. J. *see* ROBINSON, F. P.
HAMILTON, M. J., ASHBY, L., COHEN, A. F., LETLEY, E. & PECK, A. W. A comparative study of acrivastine and terfenadine on histamine (H_1-receptor) antagonism in skin and central actions in man, 283P
HARDY, C. C., HOLGATE, S. T. & ROBINSON, C. The role of prostaglandin D_2 in asthma, 518P
HARLAND, R. *see* MCELNAY, J. C.
HARPER, C. *see* RAPEPORT, W. G.
HARPER, K. W. *see* CARLISLE, R. J. T.
HARPEY, C. *see* MARIDONNEAU-PARINI, I.

HARRIES, E. H. L. *see* TABERNER, P. V.
HARRON, D. W. G., RIDDELL, J. G. & SHANKS, R. G. Effects of azepexole and clonidine on baroreceptor mediated reflex bradycardia and physiological tremor in man, 431
HARRON, D. W. G. *see* O'CONNOR, P. C.
HARRY, J. D. *see* NORRIS, S. C.
HARTEVELD, A. R. *see* WILSON, J. F.
HARVEY, J. N. *see* WORTH, D. P.
HAVARD, C. W. H. *see* NIEVEL, J. G.
HAWKSWORTH, G. M. *see* NYEMITEI-ADDO, I.
HAWKSWORTH, G. M. *see* RIGBY, J. W.
HAYNES, B. P. *see* CHOONARA, I. A.
HAYNES, B. P. *see* SCOTT, A. K.
HEAVEY, D. J., KOBZA BLACK, A., BARROW, S. E., CHAPPELL, C. G., GREAVES, M. W. & DOLLERY, C. T. Prostaglandin D_2 and histamine release in cold urticaria, 270P
HENDERSON, A. H. *see* CAMPBELL, I. A.
HENDERSON, A. H. *see* FRASER, A. G.
HENE, R. J. *see* VAN SCHAIK, B. A. V.
HENGEN, N. *see* GLEITER, C. H.
HENRY, D. A., SOMERVILLE, K. W., KITCHINGMAN, G. K., HOLMES, I. B., TOBERT, J. A. & LANGMAN, M. J. S. L-643.441: an H_2-receptor antagonist with potent and long-lasting effects in man, 133
HENRY, J. F. *see* FORETTE, F.
HENRY, P. Pharmacology and pharmacokinetics, session summary — first international symposium on nicardipine, 50S
HENSBY, C. N. *see* KOBZA BLACK, A.
HERMANOVICH, J. *see* SCHEIDT, S.
HERVY, M. P. *see* FORETTE, F.
HESKETH, R. Intracellular calcium regulation and the measurement of free calcium in 2H3 cells and synaptosomes, 221S
HIGGENS, C. S. *see* BUTLER, R. C.
HIGGINS, D. A. *see* CAMPBELL, I. A.
HILL, T. W. K. *see* ELBAHIE, N.
HILLIS, W. S. *see* CAMPBELL, B. C.
HOBSON, D. *see* WINSTANLEY, P. A.
HOCKINGS, N., AJAYI, A. A. & REID, J. L. The effects of age on the pharmacokinetics and dynamics of the angiotensin converting enzyme inhibitors enalapril and enalaprilat, 262P
HOHE, M. *see* DUKA, TH.
HOLGATE, S. T. *see* HARDY, C. C.
HOLLINGWORTH, P. *see* BUTLER, R. C.
HOLMES, I. B. *see* HENRY, D. A.
HOLT, D. W. *see* ADAMS, P. C.
HOPKINS, K. *see* SHAW, P. N.
HOPKINS, R. *see* DENNIS, M. J.
HORNUNG, R. S. *see* JONES, R. I.
HORTON, R. W. *see* THEODOROU, A. E.
HOSIE, J. *see* GEORGE, C. F.
HOSIE, J. *see* GOULD, S.
HOTCHKISS, S. A. *see* CALDWELL, J.
HOUSTON, J. B. *see* SHAFFER, J. L.
HOUSTON, J. B. *see* SHAW, P. N.
HOVI-VIANDER, M., KANTO, J., SCHEININ, H. & SCHEININ, M. Tofisopam and midazolam in clinical effects and in changes of CSF monoamine metabolites, 492
HOWDEN, C. W., FORREST, J. A. H., MEREDITH, P. A. & REID, J. L. Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man, 137
HOWELLS, R. E. *see* RIVIERE, J. H.
HOWES, L. G. & REID, J. L. Decreased vascular responsiveness to noradrenaline following regular ethanol consumption, 669
HOWES, L. G. & REID, J. L. Changes in plasma noradrenaline, 3,4-dihydroxyphenylethylene glycol and blood pressure following acute ethanol administration, 267P
HUDSON, R. J. *see* GUAY, D. R. P.
HUGHES, D. M. A. *see* MEREDITH, P. A.
HULSE, J. D. *see* ACHARI, R.
HULTHEN, U. L., BOLLI, P. & BUHLER, F. R. Vasodilatory effect of nicardipine and verapamil in the forearm of hypertensive as compared with normotensive man, 62S
HUNTER, K. R. *see* LOWE, C. H.
HUTCHINGS, A., WATT, A. H., SPRAGG, B. P., STEPHENS, M. R. & ROUTLEDGE, P. A. A high performance liquid chromatographic assay of amiodarone and desethylamiodarone in plasma, 299P
HUTCHINGS, A. *see* BENTLEY, D. P.

IDLE, J. R. *see* WYNNE, H. L.
IDOWU, O. R. *see* SALAKO, L. A.
ILETT, K. F. *see* KEMP, J.
INAGAKI, D. *see* TAKENAKA, T.
INGS, R. M. J. *see* CAMPBELL, D. B.
INGS, R. M. J. *see* DEBBAS, N. M. G.
ISLES, T. E. *see* DOW, R. J.
ISLES, T. E., BATY, J. & DOW, R. J. The effect of nicardipine on pituitary hormone release in normal volunteers, 84S

JAAKKOLA. A. *see* NEUVONEN, P. J.
JAARSMA, W. *see* VISSER, C. A.
JACKSON, N. C., LEE, P. S., REYNOLDS, G., FRAIS, M. & TAYLOR, S. H. Improvement of treadmill time to angina by amlodipine, 248P
JACKSON, N. C. *see* FRAIS, M. A.
JACKSON, N. C. *see* SILKE, B.
JACKSON, N. C. *see* TAYLOR, S. H.
JACKSON, P. R. *see* LEWIS, R. V.
JACKSON, P. R., LEWIS, R. V. & RAMSAY, L. E. β-adrenoceptor antagonists and deafness, 274P
JACKSON, P. R. *see* SANCHEZ-MARTINEZ, V.
JACKSON, S. H. D., WIFFEN, J. K., SMYTHE, M. M. & JOHNSTON, A. Circadian variation in theophylline 'trough' serum concentrations — a reply, 719
JACKSON, S. H. D. *see* DEBBAS, N. M. G.
JACOBS, C. *see* MATRE, H.
JACOBSON, S. *see* BRORS, O.
JACOLOT, D. S. *see* GIUDICELLI, J. F.
JAMES, O. F. W. *see* WOODHOUSE, K. W.
JAMIESON, M. *see* WEBSTER, J.
JANI, B. *see* LONGMORE, J.
JANZON, K., EDGER, B., LUNDBORG, P., NYBERG, G. & REGARDH, C.-G. Correlation between dose, plasma levels and effects of felodipine in healthy subjects, 250P
JAWAD, S., OXLEY, J. R., YUEN, W. C. & RICHENS, A. Reduction of interictal electroencephalographic spikes by lamotrigine in epileptic patients, 287P

JEFFERSON, D., BIRMINGHAM, A. T., WHARRAD, H. J. & PATRICK, J. M. Reduction of essential tremor by ICI 118551, a selective β_2-adrenoceptor antagonist, 244P
JENNINGS, F. *see* CHAN, K.
JOHANSSON, L. *see* ELBAHIE, N.
JOHNSON, R. F. *see* SECOR, J. W.
JOHNSON, R. H. *see* EISENHOFER, D. G.
JOHNSTON, A. *see* JACKSON, S. H. D.
JOHNSTON, A., WARRINGTON, S. & TURNER, P. Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH, 333
JOHNSTON, G. D. *see* FINCH, M. B.
JOHNSTON, G. D., FINCH, M. B., MCNEILL, J. A. & SHANKS, R. G. A comparison of the cardiovascular effects of (+)-sotalol and (±)-sotalol following intravenous administration in normal volunteers, 507
JOHNSTON, I. D. A. *see* BURGESS, P.
JONCKHEER, M. H. *see* DUPONT, A. G.
JONES, A. L., GRAINGER, S. L. & SMITH, S. E. The elimination of treatment predictability in double-blind studies, 428L
JONES, C. R., PASANISI, F., ELLIOTT, H. L. & REID, J. L. Effects of verapamil and nisoldipine on human platelets: *in vivo* and *in vitro* studies, 191
JONES, R. I., HORNUNG, R. S., SONECHA, T. & RAFTERY, E. B. The effect of nicardipine on ambulatory blood pressure and the pressor response to static and dynamic exercise, 114S
JONKMAN, J. H. G. *see* SMOLENSKY, M. H.
JONSSON, U. E. *see* NYBERG, G.
JUPE, D. M. L. *see* PETERSON, G. M.

KALRA, P. *see* FRAIS, M. A.
KAMPMANN, J. P. *see* BONDE, J.
KAMPMANN, J. P. *see* KAY, L.
KAN, G. *see* VISSER, C. A.
KANGLE, P. R. *see* RAY, K.
KANTO, J. *see* HOVI-VIANDER, M.
KATONA, C. L. E. *see* THEODOROU, A. E.
KAY, A. B. Inflammatory cells in asthma, 521P
KAY, L., KAMPMANN, J. P., SVENDSEN, T. L., VERGMAN, B., MOLHOLM HANSEN, J. E., SKOVSTED, L. & KRISTENSEN, M. Influence of rifampicin and isoniazid on the kinetics of phenytoin, 323
KAYE, C. M. *see* MITCHELL, P.
KAYE, C. M. *see* NIEVEL, J. G.
KAYE, S. B. *see* KERR, D. J.
KEEN, C. W. *see* YAP, A. K. L.
KELLY, J., DOYLE, G., DONOHOE, J., LAHER, M., VANDENBURG, M. J., CURRIE, W. J. C. & COOPER, W. D. Chronic dose pharmacokinetics of enalapril in renal impairment, 264P
KELLY, J. *see* MORRIS, F. P.
KELLY, J. G. *see* MILLIGAN, J. G. L.
KELLY, J. S. *see* THEODOROU, A. E.
KELMAN, A. W. *see* AJAYI, A. A.
KELMAN, A. W. *see* CAMPBELL, B. C.
KELMAN, A. W. *see* KERR, D. J.
KELMAN, A. W. *see* MEREDITH, P. A.
KEMP, J., ILETT, K. F., BOOTH, J. & HACKETT, L. P. Excretion of doxepin and *N*-desmethyldoxepin in human milk, 497
KENICER, K. J. A. *see* FERGUSON, J.
KERR, D. J., GRAHAM, J., BLACKIE, R. G., MCGOVERN, E., KELMAN, A. W., CUNNINGHAM, D. & KAYE, S. B. The relationship between steady state metoclopramide levels and control of emesis during treatment with cis-platinum, 426L
KERWIN, R. W., DAVIES, G. J., CHIERCHIA, S., BENCIVELLI, V., MORGAN, M. & MASERI, A. Adverse effects of dopamine in patients with ischaemic heart disease, 269P
KHURMI, N. S. *see* BOWLES, M. J.
KIMER, G. R. *see* VANDENBERG, M. J.
KINSELLA, A. *see* O'BOYLE, C. A.
KIRBY, J. D. T. *see* MEYRICK THOMAS, R. D.
KIRWAN, J. R. *see* CHAPUT DE SAINTONGE, D. M.
KITCHINGMAN, G. K. *see* HENRY, D. A.
KOBZA BLACK, A., BARR, R. M., WONG, E., BRAIN, S., GREAVES, M. W., DICKINSON, R., SHROOT, B. & HENSBY, C. N. Lipoxygenase products of arachidonic acid in human inflamed skin, 185
KOBZA BLACK, A. *see* HEAVEY, D. J.
KOLLOCH, R., STUMPE, K. O. & OVERLACK, A. Blood pressure, heart rate and A-V conduction response to nicardipine in hypertensive patients receiving atenolol, 130S
KOOLEN, J. J. *see* VISSER, C. A.
KORN, A. *see* CZECH, T.
KOSHIDA, H. *see* MIYAMORI, I.
KOVACS, I. B. *see* SOWEMIMO-COKER, S. O.
KRAUSE, L. B. & SHUSTER, S. Enhanced weal and flare response to histamine in chronic idiopathic urticaria, 486
KRISTENSEN, M. *see* KAY, L.
KUHN, S. *see* MUCKLOW, J. C.

LAHAR, M. *see* COOPER, W. D.
LAHER, M. *see* KELLY, J.
LAJOIE, D. *see* VAROQUAUX, O.
LAMBE, R. *see* PUOZZO, C.
LAMBERT, D. *see* WILLIAMS, F. M.
LAMBIE, D. G. *see* EISENHOFER, D. G.
LAMMERS, J. W. J., FOLGERING, H. TH. M. & VAN HERDWAARDEN, C. L. A. Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease, 205
LANCASTER, R. *see* WYNNE, H.
LAND, G. *see* COHEN, A. F.
LAND, G. S. *see* BINNIE, C. D.
LAND, G. S. *see* COHEN, A. F.
LANGMAN, M. J. S. *see* HENRY, D. A.
LANGMAN, M. J. S. *see* SMART, H. L.
LATHAM, L. *see* RAMSAY, L. E.
LAU, E. M. C. *see* CHAN, K.
LAVERY, G. G., MIRAKHUR, R. K., GIBSON, F. M. & CLARKE, R. S. J. Comparison of edrophonium and neostigmine for antagonism of atracurium induced neuromuscular block, 255P
LAZAR, J. D. *see* ROUTLEDGE, P. A.
LECKIE, B. J. *see* MANHEM, P. J. O.
LEDINGHAM, J. *see* COOPER, W. D.
LEE, F., RICHENS, A. ROUTLEDGE, P. A. & SPENCER, M. The Welsh adverse drug reactions scheme, 272P
LEE, M. R. *see* WORTH, D. P.
LEE, P. *see* TAYLOR, S. H.
LEE, P. S. *see* JACKSON, N. C.
LEE, T. H. *see* LEWIS, R. A.

LEESER, J. & BATEMAN, D. N. Domperidone as an additional therapy in Parkinson's disease, 284P
LENNARD, M. S. *see* MCGOURTY, J. C.
LENNARD, M. S. *see* SANCHEZ-MARTINEZ, V.
LENNARD, M. S. *see* SILAS, J. H.
LENNON, J. *see* O'BOYLE, C. A.
LETLEY, E. *see* HAMILTON, M. J.
LEVENSON, J., SIMON, A. CH., BOUTHIER, J., MAAREK, B. C. & SAFAR, M. E. The effect of acute and chronic nicardipine therapy on forearm arterial haemodynamics in essential hypertension, 107S
LEWINTER, M. M. *see* SCHEIDT, S.
LEWIS, A. S., TAYLOR, G., WILLIAMS, H. O. & LEWIS, M. H. Comparison of venous and capilliary blood sampling for the clinical determination of tobramycin serum concentrations, 597
LEWIS, L. D. & BENNETT, P. N. The pharmacology of a combined spironolactone and propranolol tablet in hypertensive patients, 536P
LEWIS, M. H. *see* LEWIS, A. S.
LEWIS, M. J. *see* FRASER, A. G.
LEWIS, R. A., LEE, T. H., SOBERMAN, R. J., WILLIAMS, J. D. & AUSTEN, K. F. Leukotrienes and asthma, 518P
LEWIS, R. V., TONER, J. M., JACKSON, P. R. & RAMSAY, L. E. Effects of sulindac and indomethacin on the blood pressure of hypertensive patients, 252P
LEWIS, R. V. *see* JACKSON, P. R.
LEWIS, R. V., JACKSON, P. R. & RAMSAY, L. E. Measuring β-adrenoceptor blocker side effects by visual analogue scales: reproducibility of scoring, 275P
LIE, K. I. *see* VISSER, C. A.
LILLYWHITE, K. J. *see* ROBSON, R. A.
LILLYWHITE, K. J. *see* MINERS, J. O.
LITTLER, W. A. *see* MACE, P. J. E.
LITTLER, W. A. *see* YOUNG, M. A.
LITTLER, W. A. & YOUNG, M. A. The effect of nicardipine on blood pressure, its variability and reflex cardiac control, 115S
LOH, W. *see* WOODCOCK, B. G.
LONGMORE, J., BRADSHAW, C. M. & SZABADI, E. Effects of locally and systematically administered antagonists on the secretory response of human eccrine sweat glands to carbachol, 1
LONGMORE, J., JANI, B., BRADSHAW, C. M. & SZABADI, E. Responses of human sweat glands to acetylcholine and carbachol: effects of cholinesterase inhibitors, 526P
LOWE, C. H., DANESHMEND, T. K. & HUNTER, K. R. The effect of guar on bumetanide-induced diuresis, 544P
LUMLEY, C. E., WALKER, S. R., HALL, G. C., STAUNTON, N. & GROB, P. Adverse drug reactions in general practice, 273P
LUMLEY, P. *see* THOMAS, M.
LUNDBORG, P. *see* JANZON, K.
LUSCOMBE, D. K. *see* TAYLOR, B. A.
LUSCOMBE, D. K. *see* YAP, A. K. L.
LUZIO, S. D. *see* VORA, J.

MAAREK, B. C. *see* SIMON, A. CH.
MACDONALD, K. J. S. *see* FERGUSON, J.
MACE, P. J. E., STALLARD, T. J. & LITTLER, W. A. The effect of felodipine on forearm haemodynamics and the myogenic response of the forearm resistance vessels in normal man, 383
MACKAY, I. G., MACNICOL, A. M., SMITH, H. J., CUMMING, A. D. & WATSON, M. L. Intrinsic sympathomimetic activity of cardioselective β-adrenoceptor blockers and effects on renal function, 197
MACNICOL, A. M. *see* MACKAY, I. G.
MADDOCKS, J. L. *see* SZAWLOWSKI, P. W. S.
MANHEM, P. J. O., BALL, S. G., MORTON, J. J., MURRAY, G. D., LECKIE, B. J., FRASER, R. & ROBERTSON, J. I. S. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man
MARIDONNEAU-PARINI, I. & HARPEY, C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells, 148
MARKS, C. *see* MORRIS, F. P.
MARSHALL, R., GRIFFITHS, A. N. & RICHENS, A. A microcomputer system to assess CNS depression from an analysis of the dynamics of saccadic eye-movements, 304P
MARSHALL, R. W. *see* ABILA, B.
MARSHALL, R. W. *see* ALI, N. A.
MARSHALL, R. W. *see* WILSON, J. F.
MASERI, A. *see* KERWIN, R. W.
MATHESON, I., SANDE, H. A., GAILLOT, J. & VEGDAHL, K. Zopiclone excretion in breast milk, 290P
MATHEWS, H. L. M. *see* WILSON, C. M.
MATIER, W. L. *see* ACHARI, R.
MATRE, H., SARI, R., TABURET, A. M., JACOBS, C. & SINGLAS, E. Haemodialysis does not affect the pharmacokinetics of nifedipine, 155
MATTHEWS, M. P. *see* MCELNAY, J. C.
MATUSSEK, N. *see* DUKA, TH.
MAURI, M. *see* ALTAMURA, A. C.
MCCAFFERTY, D. F. *see* MCELNAY, J. C.
MCCAFFREY, P., RIDDELL, J. G. & SHANKS, R. G. Comparison of the partial agonist activity of β-adrenoceptor blocking drugs in man by measurement of sleeping heart rate, 538P
MCCLELLAND, G. R. & RAPTOPOULOS, P. Cardiovascular effects of paroxetine and amitriptyline after repeated administration to normal volunteers, 282P
MCCREDIE, R. M., MCKENZIE, W. B. & MCGILL, D. A. The acute haemodynamic effects of oral nicardipine, 163S
MCDEVITT, D. G. *see* O'CONNOR, P. C.
MCELNAY, J. C., MATTHEWS, M. P., HARLAND, R. & MCCAFFERTY, D. F. The effect of ultrasound on the percutaneous absorption of lignocaine, 421
MCEWAN, J. *see* QUIGLEY, C.
MCGILL, D. A. *see* MCCREDIE, R. M.
MCGOURTY, J. C., SILAS, J. H. & COWEN, K. J. Controlled trial of ketanserin in hypertension, 37
MCGOURTY, J. C., SILAS, J. H., LENNARD, M. S., TUCKER, G. T. & WOODS, H. F. Metoprolol metabolism and debrisquine oxidation polymorphism — population and family studies, 555
MCGOURTY, J. C., SILAS, J. H., LENNARD, M. S., TUCKER, G. T. & WOODS, H. F. Verapamil kinetics and cardiovascular effects in patients during combined treatment with propranolol or atenolol, 251P

McGovern, E. *see* Kerr, D. J.
McKenzie, W. B. *see* McCredie, R. M.
McLean, S. *see* Peterson, G. M.
McNeill, A. J. *see* Pringle, T. H.
McNeill, J. A. *see* Johnston, G. D.
Meatherall, R. C. *see* Guay, D. R. P.
Meechan, J. G. & Rawlins, M. D. The effect of adrenaline in lignocaine anaesthetic solutions on serum potassium levels, 521P
Meffin, P. J., Sallustio, B. C., Purdie, Y. J., Robson, R. A., Wing, L. M. H. & Brooks, P. M. Cortisol does not inhibit prednisolone clearance, 414
Meijer, J. W. A. *see* Binne, C. D.
Mekki, Q. A. *see* Pinney, H.
Melnick, S. C. *see* Cooper, W. D.
Meredith, C. G. *see* Secor, J. W.
Meredith, P. A., Elliott, H. L., Pasanisi, F., Kelman, A. W., Sumner, D. J. & Reid, J. L. Verapamil pharmacokinetics and apparent hepatic and renal blood flow, 101
Meredith, P. A., Pasanisi, F., Elliott, H. L. & Reid, J. L. The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow, 235
Meredith, P. A., Scott, P. W., Sumner, D. J., Campbell, L., Hughes, D. M. A., Rubin, P. C. & Reid, J. L. The effect of age on the pharmacokinetics of trimazosin, 533P
Meredith, P. A. *see* Ajayi, A. A.
Meredith, P. A. *see* Howden, C. W.
Meredith, P. A. *see* O'Connor, P. C.
Meredith, P. A. *see* Vincent, J.
Meyer, U. *see* Osikowska-Evers, B. A.
Meyrick Thomas, R. H., Browne, P. D. & Kirby, J. D. T. The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin, 377
Mian, N. *see* Richardson, P. S.
Milligan, J. G. L., Kelly, J. G., Riddell, J. G. & Shanks, R. G. The effect of pindolol and its enantiomers on cyclic AMP production by human lymphocytes, 537P
Miners, J. O. *see* Robson, R. A.
Miners, J. O. *see* Wing, L. M. H.
Miners, J. O., Wing, L. M. H., Lillywhite, K. J. & Robson, R. A. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man, 219
Mirakhur, R. K. *see* Lavery, G. G.
Mitchell, P. *see* Braverman, A. M.
Mitchell, P. *see* Nievel, J. G.
Mitchison, H. C. *see* Woodhouse, K. W.
Miyamori, I., Morise, T., Yasuhara, S., Takeda, Y., Koshida, H. & Takeda, R. Single-blind study of epoprostenol and 6-keto-prostaglandin E_1 in man: effects of platelet aggregation and plasma renin, 681
Molholm Hansen, J. E. *see* Kay, L.
Molyneux, S. G. & Nutt, D. J. Studies on plasma free 3-methoxy-4-hydroxyphenylglycol in man, 541P
Molyneux, S. G. *see* Nutt, D. J.
More, D. G., Watson, C. J., Boutagy, J. S. & Shenfield, G. M. Pharmacokinetics of raniditine in quadraplegics, 166
Morgan, M. *see* Kerwin, R. W.
Morgan, W. K. C. *see* Pearson, M. G.
Morise, T. *see* Miyamori, I.
Morley, A. R. *see* Adams, P. C.
Moore, J. *see* Wilson, J. W.
Morris, F. P., Tamrazian, S., Marks, C., Kelly, J., Stephens, J. D. & Vandenberg, M. J. An acute pharmacokinetic study of the potential interaction of lisinopril and digoxin in normal volunteers, 281P
Morrison, P. J. *see* Bradbrook, I. D.
Morselli, P. L. *see* Shaw, P. N.
Morton, J. J. *see* Manhem, P. J. O.
Morton, P. *see* Norris, S. C.
Mroszczak, E. J. *see* Graham, D. J. M.
Mucklow, J. C. *see* Blain, P. G.
Mucklow, J. C. & Kuhn, S. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with a rapid theophylline clearance, 589
Muller, P. *see* Silke, B.
Mulligan, I. P. *see* Fraser, A. G.
Murray, F. *see* O'Boyle, C. A.
Murray, G. D. *see* Manhem, P. J. O.
Murray, S. *see* Clare Kahn, G.
Mutch, E. *see* Woodhouse, K. W.
Mutch, E. *see* Williams, F. M.

Nafeh, M. A. *see* El-Raghy, I.
Neuvonen, P. J., Jaakkola, A., Totterman, J. & Pentila, O. Clinically significant sucralfate-warfarin interaction is not likely, 178L
Nicholls, P. J. *see* Dalrymple, P. D.
Nicholson, A. N. & Pascoe, P. P. Hypnotic activity of an imidazo-pyridine (SL 80-0750), 257P
Nievel, J. G., Havard, C. W. H., Mitchell, P., Gudgeon, A. & Kaye, C. M. The effect of meal size on the plasma kinetics of ketoprofen after a single oral dose of 'Oruvail', 549P
Nilsson, B. *see* Nyberg, G.
Nilsson, E. *see* Gleiter, C. H.
Nordin, C., Bertilsson, L. & Siwers, B. CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite, 411
Norris, S. C., Harry, J. D., Smith, H. J., Morton, P. & Cook, S. K. Does ISA alter subjective awareness of β-adrenoceptor blockade? 242P
Nortey, L. N. *see* Adjepon-Yamoah, K. K.
Nutt, D. J. *see* Molyneux, S. G.
Nutt, D. J. & Molyneux, S. G. Plasma 3-methoxy-4-hydroxyphenylglycol and the clonidine challenge test in man, 542P
Nyberg, G. Intrinsic sympathomimetic activity of bopindolol, a non-selective β-adrenoceptor antagonist, 242P
Nyberg, G., Blychert, L.-O. & Jonsson, U. E. Pharmacokinetics of isoorbide-5-mononitrate in a controlled release (Durules) formulation, 541P
Nyberg, G. *see* Janzon, K.
Nyberg, G. & Nilsson, B. Anti-anginal efficacy of isosorbide-5-mononitrate in a controlled release (Durules) formulation, 540P
Nyemitei-Addo, I., Ewen, S. W., Petrie, J. C., Hawksworth, G. M. The relaxant effect of hydralazine in human radial artery *in vitro* is not endothelium dependent, 276P

O'Boyle, C. A., Murray, F., Lennon, J., Kinsella, A. & Crowe, J. Multivariate assessment of oral benzodiazepine anxiolysis in endoscopy, 527P
O'Brien, J., Posner, J. & Thompson, D. G. Effect of antidiarrhoael drugs on upper gastrointestinal transit determined by H_2 breath test in healthy volunteers, 294P
O'Connor, P. C., Finch, M. J., Harron, D. W. G., Meredith, P. A., McDevitt, D. G. & Shanks, R. G. Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers, 659
O'Hara, M. J. *see* Bowles, M. J.
Oates, N. S. *see* Wynne, H.
Ofori-Adjei, D. *see* Adjepon-Yamoah, K. K.
Oh, V. M. S., Chia, B. L. & Taylor, E. A. Effects of long-acting propranolol on blood pressure and heart rate in hypertensive Chinese, 144
Oh, V. M. S. & Taylor, E. A. Effects of corticosteroids on rubidium-86 uptake and [^{3}H]-ouabain binding in intact human lymphocytes *in vitro*, 278P
Oliver, D. J. The use of the syringe driver in terminal care, 515L
Orme, M. L'E. *see* Chan, K.
Orme, M. L'E. *see* Crawford, P.
Orme, M. L'E. *see* El-Raghy, I.
Osikowska-Evers, B. A., Robertz, G. M., Dayer, P., Meyer, U. & Eichelbaum, M. Kinetics of sparteine metabolism in human liver microsomes, 531P
Osman, F. *see* El-Raghy, I.
Overlack, A. *see* Kolloch, R.
Overweg, J. *see* Binne, C. D.
Owen, F., Chambers, D. R., Cooper, S. J., Crow, T. J. & Poulter, M. Tritiated imipramine binding in post-mortem brains of suicide victims, 259P
Owen, F. *see* Farmery, S. M.
Owens, D. R. *see* Vora, J.
Oxley, J. R. *see* Jawad, S.

Pacha, W. L. *see* Carruthers, S. G.
Park, B. K. *see* Choonara, I. W.
Park, B. K. *see* Choonara, B. K.
Park, B. K. *see* Scott, A. K.

Pasanisi, F. *see* Elliott, H. L.
Pasanisi, F. *see* Jones, C. R.
Pasanisi, F. *see* Meredith, P. A.
Pascoe, P. P. *see* Nicholson, A. N.
Patat, A. & Foulhoux, P. Effect of postural sway of various benzodiazepine tranquillizers, 9
Patchett, P., Patchett, S. M. & Sherwood Burge, P. Bronchial and cardiovascular responses to inhaled reproterol in asthmatics: a double-blind placebo controlled dose-response study, 349
Patchett, S. M. *see* Patchett, P.
Patel, K. R. Comparison of bronchodilator effect of tulobuterol and salbutamol aerosols in patients with asthma, 717
Patrick J. M. *see* Jefferson, D.
Paykel, E. S. *see* Theodorou, A. E.
Pays, M. *see* Varoquaux, O.
Pearce, F. L. Calcium and mast cell activation, 267S
Pearson, M. G., Ahmad, D., Chamberlain, M. J., Morgan, W. K. C. & Vinitski, S. Aminophylline and mucociliary clearance in patients with irreversible airflow limitation, 688
Pease, C. T. *see* Butler, R. C.
Peck, A. W. *see* Cohen, A. F.
Peck, A. W. *see* Hamilton, M. J.
Peck, A. W. *see* Posner, J.
Peck, A. W. *see* Yuen, W. C.
Pedersen, L. E. *see* Bonde, J.
Peel, T. *see* Ebden, P.
Penttila, O. *see* Neuvonen, P. J.
Pepine, C. J. & Gelman, J. S. Prevention of vasospastic angina with nicardipine, 187S
Peters, J. R. *see* Evans, P. J.
Peterson, G. M., McLean, S., Jupe, D. M. L., Griffith, R. L. & Roberts, J. R. A model which predicts maintenance warfarin dosage requirements from the response to a single dose, 177L
Petrie, J. C. *see* Nyemitei-Addo, I.
Petrie, J. C. *see* Rigby, J. W.
Petrie, J. C. *see* Webster, J.
Philip-Joet, F. *see* Bruguerolle, B.
Phillipson, R. *see* Posner, J.
Philpot, R. M. *see* Doyle, M. C.
Pidgen, A. *see* Swift, C. G.
Pinney, H., Edgar, D., Stewart-Jones, J. H., Mekki, Q. A. & Turner, P. Relationship between pupil size and intraocular pressure after topical application of guanethidine and thymoxamine, 535P
Piper, P. J. *see* Barnes, N. C.
Pippen, C. *see* Arr, S. M.
Posner, J., Telekes, A., Crowley, D., Phillipson, R. & Peck, A. W. A cold induced pain model for evaluation of analgesics in healthy volunteers, 289P
Posner, J. *see* O'Brien, J.
Pouleur, H. *see* Rousseau, M. F.
Poulter, M. *see* Farmery, S. M.
Poulter, M. *see* Owen, F.
Poyard-Salmeron, C. *see* Forette, F.
Prichard, B. N. C. *see* Cronin, C. J.
Pringle, T. H., McNeill, A. J., Riddell, J. G. & Shanks, R. G. Comparison of the β-adrenoceptor blocking activity and cardioselectivity of Koe 3290 and atenolol, 537P
Pun, K. K., Yeung, C. K. & Chan, M. K. Effects of nadolol and propranolol on renal function in hypertensive patients with moderately impaired renal function, 401
Puozzo, C., Filaquier, C. & Briley, M. Plasma levels of F 2207, midalcipran, a novel antidepressant, after single oral administration in volunteers, 290P
Puozzo, C., Lambe, R. & Briley, M. Inhibition of [^{3}H]-5-HT uptake in platelets by plasma from volunteers after a single oral dose of F 2207, midalcipran, a novel antidepressant, 292P
Purdie, Y. J. *see* Meffin, P. J.

Quigley, C., McEwan, J., Di Silvo, L. & Brown, M. J. Bufuralol, a β-adrenoceptor antagonist with partial β_2-agonist activity, lowers plasma potassium in man, 243P

Raftery, E. B. *see* Caruana, M. P.
Raftery, E. B. *see* Bowles, M. J.
Raftery. E. B. *see* Jones, R. I.
Raine, A. *see* Cooper, W. D.
Ramakrishnan, S. *see* Ray, K.
Rampe, D., Su, C. M., Yousif, F. & Triggle, D. J.

Calcium channel antagonists: pharmacological considerations, 247S

RAMSAY, L. E. & LATHAM, L. Comparison of hydralazine, nifedipine and prazosin as thirdline drugs for hypertension, 524P

RAMSAY, L. E. *see* CAMERON, H. A.

RAMSAY, L. E. *see* JACKSON, P. R.

RAMSAY, L. E. *see* LEWIS, R. V.

RAMSAY, L. E. *see* SILAS, J. H.

RAO, S. K. *see* ARR, S. M.

RAPEPORT, W. G., ARONSON, J. K., GRAHAME-SMITH, D. G. & CARVER, J. G. Increased specific (^{3}H)-oubain binding to lymphocytes after incubation with acetylstrophanthidin for 3 days, 277P

RAPEPORT, W. G., ARONSON, J. K., GRAHAME-SMITH, D. G., HARPER, C. The effects of lithium, ethacrynic acid, and low potassium on specific lymphocytic (^{3}H)-oubain binding, 259P

RAPTOPOULOS, P. *see* MCCLELLAND, G. R.

RAVINDRAN, A. V. *see* DOYLE, M. C.

RAWLINS, M. D. *see* BATEMAN, D. N.

RAWLINS, M. D. *see* BLAIN, P. G.

RAWLINS, M. D. *see* FERNER, R. E.

RAWLINS, M. D. *see* MEECHAN, J. G.

RAWLINS, M. D. *see* WILLIAMS, F. M.

RAWLINS, M. D. *see* WOODHOUSE, K. W.

RAY, K., ADITHAN, C., BAPNA, J. S., KANGLE, P. R., RAY, K. & RAMAKRISHNAN, S. Effect of short surgical procedures on salivery paracetamol elimination, 174

RAY, K. *see* RAY, K.

REECE, P. A., DISNEY, A. P., STAFFORD, I. & SHASTRY, J. C. M. Prednisolone protein binding in renal transplant patients, 159

REGARDH, C.-G. *see* EDGER, B.

REGARDH, C.G. *see* JANZON, K.

REID, J. L. *see* AJAYI, A. A.

REID, J. L. *see* ELLIOTT, H. L.

REID, J. L. *see* HOCKINGS, N.

REID, J. L. *see* HOWDEN, C. W.

REID, J. L. *see* HOWES, L. G.

REID, J. L. *see* JONES, C. R.

REID, J. L. *see* MEREDITH, P. A.

REID, J. L. *see* VINCENT, J.

RENOWDEN, S. *see* FENNERTY, A. G.

RENWICK, A. G. & GEORGE, C. F. A double-blind, placebo controlled undergraduate practical, 552P

RENWICK, A. G. *see* CHALLENOR, V. F.

RENWICK, A. G. *see* GEORGE, C. F.

RENWICK, A. G. *see* ROBERTS, A.

RENWICK, A. G. *see* STRONG, H. A.

REYNOLDS, G. *see* FRAIS, M. A.

REYNOLDS, G. *see* JACKSON, N. CV.

REYNOLDS, G. *see* SILKE, B.

REYNOLDS, G. *see* TAYLOR, S. H.

REYNOLDS, G. *see* VERMA, S. P.

RIAD-FAHMY, D. *see* EVANS, P. J.

RICHARDS, R. & TATTERSFIELD, A. E. Bronchial β-adrenoceptor blockade following eyedrops of timolol and its isomer L-714,465 in normal subjects, 459

RICHARDS, R. P. *see* DEBBAS, N. M. G.

RICHARDSON, P. S., MIAN, N. & BALFRE, K. The role of calcium ions in airway secretion, 275S

RICHENS, A. *see* ABILA, B.

RICHENS, A. *see* ALI, N. A.

RICHENS, A. *see* JAWAD, S.

RICHENS, A. *see* LEE, F.

RICHENS, A. *see* MARSHALL, R. W.

RICHENS, A. *see* SMART, H. L.

RICHENS, A. *see* TEDESCHI, G.

RICHENS, A. *see* WILSON, J. F.

RICHER, C. *see* GIUDICELLI, J. F.

RIDDELL, J. G. *see* HARRON, D. W. G.

RIDDELL, J. G. *see* MCCAFFREY, P.

RIDDELL, J. G. *see* MILLIGAN, J. G. L.

RIDDELL, J. G. *see* PRINGLE, T. H.

RIETBROCK, N. *see* WOODCOCK, B. G.

RIGBY, J. W., SCOTT, A. K., HAWKSWORTH, G. M. & PETRIE, J. C. A comparison of the pharmacokinetics of ateanolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects, 327

RIVIERE, J. H., BLACK, D. J., BRECKENRIDGE, A. M. & HOWELLS, R. E. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism, 469

ROBB, O. J. *see* WEBSTER, J.

ROBERTS, A., RENWICK, A. G. & GEORGE, C. F. Salicylate pharmacokinetics — an undergraduate practical, 551P

ROBERTS, D. F. *see* BLAIN, P. G.

ROBERTS, J. R. *see* PETERSON, G. M.

ROBERTSON, J. I. S. *see* MANHEM, P. J. O.

ROBERTZ, G. M. *see* OSIKOWSKA-EVERS, B. A.

ROBINSON, C. *see* HARDY, C. C.

ROBINSON, F. P., HALLIDAY, N. J. & DUNDEE, J. W. Age-related responses to propofol in unpremedicated patients, 529P

ROBINSON, J. *see* BRADBROOK, I. D.

ROBINSON, J. *see* SWIFT, C. G.

ROBSON, R. A., WING, L. M. H., MINERS, J. O., LILLYWHITE, K. J. & BIRKETT, D. J. The effect of ranitidine on the disposition of lignocaine, 170

ROBSON, R. A. *see* MEFFIN, P. J.

ROBSON, R. A. *see* MINERS, J. O.

ROGER, I. W. Excitation-contraction coupling and uncoupling in airway smooth muscle, 255S

ROGERS, H. J. *see* BRADBROOK, I. D.

ROMBUSCH, M. *see* FERRY, D. R.

ROUSSEAU, M. F., VINCENT, M. F., CHERON, P., VAN DEN BERGHE, G., CHARLIER, A. A. & POULEUR, H. Effects of nicardipine on coronary blood flow, left ventricular inotropic state and myocardial metabolism in patients with angina pectoralis, 147S

ROUTLEDGE, P. A., LAZAR, J. D., BARCHOWSKY, A., STARGEL, W. W., WAGNER, G. S. & SHAND, D. G. A free lignocaine index as a guide to unbound drug concentration, 695

ROUTLEDGE, P. A. *see* BENTLEY, B. P.

ROUTLEDGE, P. A. *see* BLAIN, P. G.

ROUTLEDGE, P. A. *see* EBDEN, P.

ROUTLEDGE, P. A. *see* ELBAHIE, N.

ROUTLEDGE, P. A. *see* FENNERTY, A. G.

ROUTLEDGE, P. A. *see* HUTCHINGS, A.

ROUTLEDGE, P. A. *see* LEE, F.

ROUTLEDGE, P. A. *see* WATT, A. H.

ROUTLEDGE, P. A. *see* WEBB, D.

ROWLAND, M. *see* SHAW, P. N.

ROYSTON, P. *see* CARUANA, M. P.

RUBIN, P. C. *see* AJAYI, A. A.

RUBIN, P. C. *see* MEREDITH, P. A.

SAFAR, M. E. *see* SIMON, A. CH.
SALAKO, L. A. & IDOWU, O. R. Failure to detect amodiaquine in the blood after oral administration, 307
SALLUSTIO, B. C. *see* MEFFIN, P. J.
SALMOE, C. *see* BLACK, J.
SANCHEZ-MARTINEZ, V., TUCKER, G. T., JACKSON, P. R., LENNARD, M. S., BAX, N. D. S. & WOODS, H. F. Lack of effect of propranolol on the kinetics of paracetamol in man, 548P
SANDE, H. A. *see* MATHESON, I.
SARI, R. *see* MATRE, H.
SCANLON, M. F. *see* EVANS, P. J.
SCHEIDT, S., LEWINTER, M. M., HERMANOVICH, J., VENKATARAMAN, K. & FREEDMAN, D. Nicardipine for stable angina pectoris, 178S
SCHEININ, H. *see* HOVI-VIANDER, M.
SCHEININ, M. *see* HOVI-VIANDER, M.
SCHENKER, S. *see* SECOR, J. W.
SCHWARTZ, J. B. *see* ABERNETHY, D. R.
SCHWEMER, G. *see* GEORGHIADE, M.
SCOLDING, N. J. *see* FENNERTY, A. G.
SCOTT, A. K. *see* CHOONARA, I. A.
SCOTT, A. K., HAYNES, B. P. & PARK, B. K. Hepatic enzyme induction by anticonvulsants and vitamin K_1 elimination, 301P
SCOTT, A. K. *see* RIGBY, J. W.
SCOTT, D. *see* GEORGE, C. F.
SCOTT, J. T. *see* BUTLER, R. C.
SCOTT, P. H. *see* SMOLENSKY, M. H.
SCOTT, P. W. *see* MEREDITH, P. A.
SECOR, J. W., VINCENT SPEEG JR, K., MEREDITH, C. G., JOHNSON, R. F., SNOWDY, P. & SCHENKER, S. Lack of effect of nizatidine on hepatic drug metabolism in man, 710
SEDDON, T., BOOBIS, A. R. & DAVIES, D. S. Drug metabolizing activity of cryopreserved rat and human hepatocytes, 446P
SHAFFER, J. L., TURNER, M. & HOUSTON, J. B. Disposition of a 5-aminosalicylic acid preparation in patients with inflammatory bowel disease, 532P
SHAND, D. G. *see* BLAIN, P. G.
SHAND, D. G. *see* ROUTLEDGE, P. A.
SHANKS, R. G. *see* HARRON, D. W. G.
SHANKS, R. G. *see* JOHNSTON, G. D.
SHANKS, R. G. *see* MCCAFFREY, P.
SHANKS, R. G. *see* MILLIGAN, J. G. L.
SHANKS, R. G. *see* O'CONNOR, P. C.
SHANKS, R. G. *see* PRINGLE, T. H.
SHASTRY, J. C. M. *see* REECE, P. A.
SHAW, P. N., HOUSTON, J. B., ROWLAND, M., HOPKINS, K., THIERCELIN, J. F. & MORSELLI, P. L. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamzepine, 611
SHENFIELD, G. M. *see* MORE, D. G.
SHERIDAN, D. J. *see* CULLING, W.
SHERWOOD BURGE, P. *see* PATCHETT, P.
SHIBASAKI, M. *see* TAKENAKA, T.
SHILLINGFORD, J. *see* DENNIS, M. J.
SHIONO, K. *see* TAKENAKA, T.
SHROOT, B. *see* KOBZA BLACK, A.
SHUSTER, S. *see* KRAUSE, L. B.
SILAS, J. H., FREESTONE, S., LENNARD, M. S. & RAMSAY, L. E. Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients, 387
SILAS, J. H. *see* MCGOURTY, J. C.
SILKE, B., FRAIS, M.A., MULLER, P., VERMA, S.P., REYNOLDS, G. & TAYLOR, S.H. Haemodynamic dose-response effects of intravenous nisoldipine in coronary artery disease, 675
SILKE, B., VERMA, S. P. V., FRAIS, M. A., HAFIZULLAH, M. & TAYLOR, S. H. Effects of buccal nitrate on left ventricular haemodynamics and volume at rest and during exercise induced angina, 437
SILKE, B., VERMA, S. P., FRAIS, M. A., HAFIZULLAH, M. & TAYLOR, S. H. Effects of nicardipine on cardiac volume at rest and during exercise-induced angina, 169S
SILKE, B. FRAIS, M. A., VERMA, S. P., REYNOLDS, G., JACKSON, G. & TAYLOR, S. H. Haemodynamic interactions of nicardipine and metoprolol in ischaemic heart disease, 524P
SILKE, B., VERMA, S. P., FRAIS, M. A., REYNOLDS, G. & TAYLOR, S. H. Cardiac function studies with celiprolol and metoprolol in coronary artery disease, 245P
SILKE, B. *see* FRAIS, M. A.
SILKE, B. *see* TAYOR, S. H.
SILKE, B. *see* VERMA, S. P.
SIMON, A. CH. *see* LEVENSON, J.
SIMPSON, J. M. *see* BATEMAN, D. N.
SINCLAIR, A. J. *see* GRIND, I. M.
SINGH, B. N. Angina and ischaemic heart disease, session summary — first international symposium on nicardipine, 206S
SINGH, H. *see* CAMPBELL, I. A.
SINGLAS, E. *see* MATRE, H.
SIWERS, B. *see* NORDIN, C.
SIX, R. O. *see* DUPONT, A. G.
SKOVSTED, L. *see* KAY, L.
SLOAN, P. *see* ADAMS, P. C.
SMART, H. L., SOMERVILLE, K. W., WILLIAMS, J., RICHENS, A. & LANGMAN, M. J. S. The effects of sucralfate upon phenytoin absorption in man, 238
SMITH, A. T. *see* TEDESCHI, G.
SMITH, C. C. T. *see* CRONIN, C. J.
SMITH, H. J. *see* MACKAY, I. G.
SMITH, H. J. *see* NORRIS, S. C.
SMITH, R. L. *see* WYNNE, H.
SMITH, S. E. *see* JONES, S. L.
SMOLENSKY, M. H., JONKMAN, J. H. G. & SCOTT, P. H. Circadian variation in theophylline 'trough' serum concentrations, 718
SMYTHE, M. M. *see* JACKSON, S. H. D.
SNOWDY, P. *see* SCHENKER, S.
SO, A. *see* CHAN, K.
SOBERMAN, R. J. *see* LEWIS, R. A.
SOMERVILLE, K. W. *see* HENRY, D. A.
SOMERVILLE, K. W., *see* SMART, H. L.
SOMMERS, DE. K. *see* VAN WYK, M.
SOMOGYI, A. & BOCHNER, F. Ranitidine and procainamide absorption, 182L
SONECHA, T. *see* JONES, R. I.
SOWEMIMO-COKER, S. O., DEBBAS, N. M. G., KOVACS, I. B. & TURNER, P. *Ex vivo* effects of nifedipine, nisoldipine and nitrendipine on filter-

ability of red blood cells from healthy volunteers, 152
SPECTOR, R. G. *see* BRADBROOK, I. D.
SPENCER, M. *see* LEE, F.
SPRAGG, B. P. *see* BENTLEY, D. P.
SPRAGG, B. P. *see* EBDEN, P.
SPRAGG, B. P. *see* HUTCHINGS, A.
ST CLAIR, J. *see* GEORGHIADE, M.
ST CLAIR, C. *see* GEORGHIADE, M.
STAFFORD, I. *see* REECE, P. A.
STALLARD, T. J. *see* MACE, P. J. E.
STALLARD, T. J. *see* YOUNG, M. A.
STARGEL, W. W. *see* ROUTLEDGE, P. A.
STAUNTON, N. *see* LUMLEY, C. E.
STEPHENS, J. D. *see* MORRIS, F. P.
STEPHENS, M. R. *see* HUTCHINGS, A.
STEPHENS, M. R. *see* WATT, A. H.
STEVENSEN, I. H. *see* SWIFT, C. G.
STEVENS, J., WALKER, S., BLOOM, B. & BERRY, H. Does measurement of health status have a role in the assessment of chronic diseases? 272P
STEWART-JONES, J. H. *see* PINNEY, H.
STEYN, A. G. W. *see* VAN WYK, M.
STODELL, M. A. *see* BUTLER, R. C.
STRONG, H. A., WARNER, N. J., RENWICK, A. G. & GEORGE, C. F. Sulindac activation by the gut flora, 545P
STRUTHERS, A. D. *see* BROWN, M. J.
STUMPE, K. O. *see* KOLLOCH, R.
SU, C. M. *see* RAMPE, D.
SUMNER, D. J. *see* AJAYI, A. A.
SUMNER, D. J. *see* MEREDITH, P. A.
SVENDSEN, T. L. *see* BONDE, J.
SVENDSEN, T. L. *see* KAY, L.
SWIFT, C. G., EWEN, J. M., CLARKE, P. & STEVENSON, I. H. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentration, 111
SWIFT, C. G., SWIFT, M. R., ANKIER, S. I., PIDGEN, A. & ROBINSON, J. Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly, 119
SWIFT, M. R. *see* SWIFT, C. G.
SZABADI, E. *see* LONGMORE, J.
SZAWLOWSKI, P. W. S. & MADDOCKS, J. L. Effect of interleukin-2 on the inhibition of the human mixed lymphocyte reaction (MLR) by azathioprine, 107
SZAWLOWSKI, P. W. S., AL-SAFI, S. A., DOOLEY, T. & MADDOCKS, J. L. Azathioprine suppresses the mixed lymphocyte reaction of patients with Lesch-Nyhan syndrome, 489

TABERNER, P. V., CONNELLY, D. M. & HARRIES, E. H. L. Hyperglycaemia and glucose intolerance in non-alcoholic heavy drinkers, 529P
TABURET, A. M. *see* MATRE, H.
TAKEDA, R. *see* MIYAMORI, I.
TAKEDA, S. *see* MIYAMORI, I.
TAKENAKA, T., ASANO, M., SHIONO, K., SHIBASAKI, M. & INAGAKI, D. Cardiovascular pharmacology of nicardipine in animals, 7S
TAMRAZIAN, S. *see* MORRIS, F. P.
TATTERSFIELD, A. E. *see* RICHARDS, R.
TAYLOR, B. A., DUTHIE, H. L. & LUSCOMBE, D. K. Calcium antagonist activity of methanol on gastrointestinal smooth muscle, 293P
TAYLOR, E. A. *see* OH, V. M. S.
TAYLOR, G. *see* LEWIS, A. S.
TAYLOR, S. H., FRAIS, M. A., LEE, P., VERMA, S. P., JACKSON, N., REYNOLDS, G. & SILKE, B. A study of the long term efficacy and tolerability of oral nicardipine in hypertensive patients, 139S
TAYLOR, S. H., FRAIS, M. A., LEE, P., VERMA, S. P., JACKSON, N. & SILKE, B. Anti-hypertensive dose-response effects of nicardipine in stable essential hypertension, 135S
TAYLOR, S. H. *see* FRAIS, M. A.
TAYLOR, S. H. *see* JACKSON, N. C.
TAYLOR, S. H. *see* SILKE, B.
TAYLOR, S. H. *see* VERMA, S. P.
TAYLOR, W. B. & BATEMAN, D. N. Bioavailability of high-dose metoclopramide in health and disease, 297P
TEDESCHI, G., GRIFFITHS, A. N., SMITH, A. T. & RICHENS, A. The effect of repeated doses of temazepam and nitrazepam on human psychomotor performance, 361
TELEKES, A. *see* POSNER, J.
TENKATE-WESTERHOF, E. W. D. *see* TEUNISSEN, M. W. E.
TEUNISSEN, M. W. E., BRUINING, G. J., DE JONGH, B. M., TENKATE-WESTERHOF, E. W. D. & BREIMER, D. D. Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia, 703
THEODOROU, A. E., KATONA, C. L. E., DAVIES, S. L., TUNNICLIFFE, C., HALE, A. S., HORTON, R. W., PAYKEL, E. S. & KELLY, J. S. Platelet α_2-noradrenergic and imipramine binding in depressed patients, before and during treatment, 528P
THIERCELIN, J. F. *see* SHAW, P. N.
THOMAS, J. P. *see* EVANS, P. J.
THOMAS, M., LUMLEY, P. & FOWLER, P. Effect of repeat dosing with the thromboxane receptor blocking drug AH 23848 on platlet aggregation *ex vivo* in man, 543P
THOMAS, P. *see* CULLING, W.
THOMPSON, D. G. *see* O'BRIEN, J.
THOMPSON, E. M. *see* WILSON, C. M.
TIPLADY, B. An automated test battery for the detection of changes in mental function and psychomotor performance, 304P
TIRLAPUR, V. G. *see* FRASER, A. G.
TJANDRAMAGA, T. B. *see* VAN HECKEN, A. M.
TJIA, J. *see* CRAWFORD, P.
TJIA, J. *see* WINSTANLEY, P. A.
TOBERT, J. A. *see* HENRY, D. A.
TODD, E. L. *see* ABERNETHY, D. R.
TONER, J. M. *see* LEWIS, R. V.
TOTTERMAN, J. *see* NEUVONEN, P. J.
TOVERUD, E.-L. *see* CLARE KAHN, G.
TRAWALE, J. M. *see* VAROQUAUX, O.
TRIGGLE, D. J. Calcium ions and respiratory smooth muscle function, 213S
TRIGGLE, D. J. *see* RAMPE, D.
TROUT, S. J. *see* BURLEIGH, D. E.
TSANACLIS, L. *see* EVANS, P. J.
TSE, J. *see* CHAN, K.
TUCKER, G. T. *see* BAX, N. D. S.
TUCKER, G. T. *see* MCGOURTY, J. C.
TUCKER, G. T. *see* SANCHEZ-MARTINEZ, V.
TUNNICLIFFE, C. *see* THEODOROU, A. E.

TURNER, M. *see* SHAFFER, J. L.
TURNER, P. *see* DEBBAS, N. M. G.
TURNER, P. *see* JOHNSTON, A.
TURNER, P. *see* PINNEY, H.
TURNER, P. *see* SOWEMIMO-COKER, S. O.

UKENA, D. *see* FRIEBEL, P.
UNSWORTH, J. *see* COOPER, W. D.

VAN DEN BERGHE, G. *see* ROUSSEAU, M. F.
VAN EMDE BOAS, W. *see* BINNIE, C. D.
VAN HECHEN, A. M., TJANDRAMAGA, T. B., VERBESSELT, R. & DE SCHEPPER, P. J. The influence of diflunisal on the pharmacokinetics of oxazepam, 225
VAN HERWAARDEN, C. L. A. *see* LAMMERS, J. W. J.
VAN HERWAARDEN, C. L. A. *see* WIJNANDS, W. J. A.
VAN SCHAIK, B. A. V., HENE, R. J. & GEYSKES, G. G. Influence of nicardipine on blood pressure, renal function and plasma aldosterone in normotensive volunteers, 88S
VAN WIERINGEN, A. *see* BINNIE, C. D.
VAN WYK, M., SOMMERS, DE K. & STEYN, A. G. W. Evaluation of gastrointestinal motility using the hydrogen breath test, 479
VAN YPERSELE DE STRIHOU, C. Hypertension, session summary — first international symposium on nicardipine, 143S
VANDENBURG, M. J., COOPER, W. D. & KIMBER, G. R. Does the lack of patient knowledge about glyceryl trinitrate limit the usefulness of the drug? 246P
VANDENBERG, M. J. *see* COOPER, W. D.
VANDENBURG, M. J. *see* KELLY, J.
VANDENBERG, M. J. *see* MORRIS, F. P.
VANDERNIEPEN, P. *see* DUPONT, A. G.
VAROQUAUX, O., LAJOIE, D., GOBERT, C., CORDONNIER, P., DUCREUZET, C., PAYS, M. & ADVENIER, C. Pharmacokinetics of the trimethoprim-sulphoxazole combination in the elderly, 575
VAROQUAUX, O., TRAWALE, J. M., DOLL, J., ANDRIEU, J., GROSBUIS, S., PAYS, M. & ADVENIER, C. Pharmacokinetics of ranitidine in acute upper gastrointestinal haemorrhage, 699
VEGDAHL, K. *see* MATHESON, I.
VENKAT RAMAN, G. *see* COOPER, W. D.
VENKATARAMAN, K. *see* SCHEIDT, S.
VERBESSELT, R. *see* VAN HECKEN, A. M.
VERGMAN, B. *see* KAY, L.
VERMA, S. P., SILKE, B., FRAIS, M. A., REYNOLDS, G. & TAYLOR, S. H. Effects of buccal glyceryl trinitrate on cardiac volume in coronary artery disease, 245P
VERMA, S. P. *see* FRAIS, M. A.
VERMA, S. P. *see* SILKE, B.
VERMA, S. P. *see* TAYLOR, S. H.
VERSCHUEREN, J. *see* WEBSTER, J.
VINCENC, K. *see* BLACK, J.
VINCENT, J., ELLIOTT, H. L., MEREDITH, P. A. & REID, J. L. The effect of age on the pharmacokinetics and pharmacodynamics of doxazosin, 251P
VINCENT, M. F. *see* ROUSSEAU, M. F.
VINCENT SPEEG JR, K. *see* SECOR, J. W.
VINITSKI, S. *see* PEARSON, M. G.
VISSER, C. A., JAARSMA, W., KAN, G., KOOLEN, J. J. & LIE, K. I. Immediate and long-term effects of nicardipine, at rest and during exercise, in patients with coronary artery disease, 158S
VORA, J., OWENS, D. R., LUZIO, S. D. & DAVIES, G. J. A comparison of the metabolic response to glucagon and glucagon 1-21 peptide in normal individuals and NIDDM patients, 271P
VREE, T. B. *see* WIJNANDS, W. J. A.

WAGNER, G. S. *see* ROUTLEDGE, P. A.
WALDEN, R. J. *see* CRONIN, C. J.
WALKER, R. F. *see* EVANS, P. J.
WALKER, S. *see* STEVENS, J.
WALKER, S. R. *see* LUMLEY, C. E.
WALLER, D. *see* CHALLENOR, V. F.
WALTER-SACK, I. *see* FRIEBEL, P.
WARNER, N. J. *see* STRONG, H. A.
WARRINGTON, S. *see* JOHNSTON, A.
WARRINGTON, S. J. *see* GRIND, I. M.
WATSON, C. J. *see* MORE, D. G.
WATSON, M. L. *see* MACKAY, I. G.
WATSON, R. D. S. *see* YOUNG, M. A.
WATT, A. H. & ROUTLEDGE, P. A. Adenosine stimulates respiration in man, 503
WATT, A. H., STEPHENS, M. R., BUSS, D. C. & ROUTLEDGE, P. A. Amiodarone reduces plasma warfarin clearance in man, 707
WATT, A. H. *see* HUTCHINGS, A.
WEBB, D., BUSS, D. C., FIFIELD, R., BATEMAN, D. N. & ROUTLEDGE, P. A. The plasma protein binding of metoclopramide in health and renal disease, 297P
WEBER, E. *see* FRIEBEL, P.
WEBSTER, J., PETRIE, J. C., ROBB, O. J., JAMIESON, M. & VERSCHUEREN, J. A comparison of single doses of bucindolol and oxprenolol in hypertensive patients, 393
WHARRAD, H. J. *see* JEFFERSON, D.
WIDDICOMBE, J. G. Possible role of calcium in neurotransmission to the lower airways, 281S
WIFFEN, J. K. *see* JACKSON, J. K.
WIJNANDS, W. J. A., VREE, T. B. & VAN HERWAARDEN, C. L. A. Enoxacin decreases the clearance of theophylline in man, 583
WILLIAMS, F. M., MUTCH, E., WOODHOUSE, K. W., LAMBERT, D. & RAWLINS, M. D. Ethoxyresorufin *O*-diethylation by human liver, 302P
WILLIAMS, F. M., WOOLHOUSE, N. M., ADJEPON-YAMOAH, K. K. & RAWLINS, M. D. Interindividual variation in plasma aspirin esterases and cholinesterases in Ghanaian and British subjects, 302P
WILLIAMS, H. O. *see* LEWIS, A. S.
WILLIAMS, J. *see* ELBAHIE, N.
WILLIAMS, J. *see* SMART, H. L.
WILLIAMS, J. *see* WILSON, J. F.
WILLIAMS, J. D. *see* LEWIS, R. A.
WILSON, A. *see* ALPS, B. J.
WILSON, C. M., DUNDEE, J. W., MOORE, J., COLLIER, P. S., MATHEWS, H. L. M. & THOMPSON, E. M. A comparison of plasma midazolam levels in non-pregnant and pregnant women at parturition, 256P
WILSON, J. F. *see* ABILA, B.
WILSON, J. F., DIJKHUIS, I. C., HARTEVELD, A. R., DEJONG, H. G., WILLIAMS, J., MARSHALL, R. W. & RICHENS, A. Influence of extraction solvents on the accuracy and precision of measurements of tricyclic antidepressants, 293P
WILSON, J. F. *see* ELBAHIE, N.
WING, L. M. H. & MINERS, J. O. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of

trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition, 482
WING, L. M. H. *see* MEFFIN, P. J.
WING, L. M. H. *see* MINERS, J. O.
WING, L. M. H. *see* ROBSON, R. A.
WINSTANLEY, P. A., TJIA, J., BACK, D. J., HOBSON, D. & BRECKENRIDGE, A. M. Lack of effect of highly purified subunit influenza vaccination on theophylline metabolism 47
WONG, E. *see* KOBZA BLACK, A.
WOODCOCK, B. G., RIETBROCK, N., LOH, W. & HABEDANK, W. -D. Absorption kinetics of dihydroergotoxine following oral administration to man, 603
WOODHEAD, J. S. *see* DAVIES, P. D. O.
WOODHOUSE, K. W., MITCHISON, H. C., MUTCH, E., WRIGHT, P. D., RAWLINGS, M. D. & JAMES, O. F. W. The metabolism of 7-ethoxycoumarin in human liver microsomes and the effect of primary biliary cirrhosis: implications for studies of drug metabolism in liver disease, 77
WOODHOUSE, K. W. *see* WILLIAMS, F. M.
WOODS, H. F. *see* BAX, N. D. S.
WOODS, H. F. *see* MCGOURTY, J. C.
WOODS, H. F. *see* SANCHEZ-MARTINEZ, V.
WOOLHOUSE, N. M. *see* ADJEPON-YAMOAH, K. K.
WOOLHOUSE, N. M. *see* WILLIAMS, F. M.
WOOLLARD, M. L. *see* ARR, S. M.
WOOLLARD, M. L. *see* COOPER, W. D.
WORRAL, A. *see* WORTH, D. P.
WORTH, D. P., HARVEY, J. N., BROWN, J., WORRAL, A. & LEE, M. R. The effect of domperidone on changes in renal function induced by the dopamine prodrug glutamyl dopa, 268P
WRIGHT, P. D. *see* WOODHOUSE, K. W.
WYNNE, H., LANCASTER, R., OATES, N. S., CROTHERS, M. J., IDLE, J. R. & SMITH, R. L. Debrisoquine, oxidation phenotyping and adverse drug reactions. Utility of phenotyping in general hospital admissions, 254P

YAP, A. K. L., FISH, R. G., KEEN, C. W. & LUSCOMBE, D. K. Disposition of methotrexate following a 6 h infusion in cancer patients, 297P
YASUHARA, S. *see* MIYAMORI, I.
YEUNG, C. K. *see* PUN, K. K.
YOUNG, M. A. *see* LITTLER, W. A.
YOUNG, M. A., WATSON, R. D. S., STALLARD, T. J. & LITTLER, W. A. Calcium channel blockers — are they diuretics, 95S
YOUSIF, F. *see* RAMPE, D.
YUEN, W. C. *see* JAWAD, S.
YUEN, W. C., PECK, A. W. & BURKE, C. A. The subjective effects of dextromethorphan, codeine and diazepam in healthy volunteers, 290P

ZAKRZEWSKI, J. T. *see* BARNES, N. C.

SUBJECT INDEX

(S = supplement; L = letter to the Editors; P = proceedings)

α-adrenoceptor blockade, 191
α-adrenoceptors, 41
α_1-acid glycoprotein, 500
α_1-adrenoceptor blockade, 247P
α_2-noradrenergic binding, 528P
Absorption, 254P
Absorption kinetics, 603
ACE inhibitors, 262P
Acetylcholine, 355, 526P
Acetylcholinesterase, 17
Acetylstrophanthidin, 277P
Acrivastine, 283P
Activated charcoal, 254P
Adenosine, 503, 520P
Adrenal hyperplasia, 703
Adrenaline, 649, 521P
Adverse drug reactions, 273P
Age, 453, 120S
AH 23848, 543P
Airway disease, 300P
Airway function, 289S
Airway secretion, 275S
Alcohol, 669
Aldosterone, 88S, 99S
Allergy, 267S
Almitrine bismesylate, 547P
Ambulatory blood pressure, 93, 115S
Ambulatory monitoring, 177S
Aminoglutethimide, 295P
Aminophylline, 688
5-aminosalicylic acid, 532P
Amiodarone, 707, 299P, 523P
Amitriptyline, 282P
Amlodipine, 248P
Amodiaquine, 307
Anaesthetic, 521P
Analgesics, 289P
Angina, 405, 437, 248P
Angina pectoris, 147S
Angiotensin, 669, 262P, 99S
Angiotensin II, 17, 88S
Angiotensin converting enzyme inhibitors, 17
Animal models, 29S
Anti-epileptic drug, 285P
Antianginal effect, 7S
Anticoagulated patients, 265P
Anticonvulsant, 129, 619, 286P, 301P
Antidepressant, 714, 291P, 292P
Antidiarrhoeal drugs, 294P
Antihypertensive effect, 7S
Antioxidant, 148
Antipyrine, 313, 469, 611, 703
Antipyrine clearance, 253P, 546P
Apparent liver blood flow, 101
Arterial blood, 597
Arterial compliance, 107S
Arthritis, 567P
Aspirin esterases, 302P
Asthma, 41, 349, 387, 405, 89L, 717L, 251P, 518P, 519P, 520P, 521P, 537P, 130S
Atracurium induced neuromuscular block, 255P
Atropine methonitrate, 1
Atropine sulphate, 1
Autonomic nervous system, 281S
Autoradiography, 107, 489, 233S
A–V conduction, 130S
Azepexole (B-HT 933), 431

β-adrenoceptor antagonist, 507, 242P, 243P, 274P, 525P
β-adrenoceptor blockade, 387, 459, 659, 242P
β-adrenoceptor blocker, 197, 327, 369, 275P, 537P, 538P
β-adrenoceptor, 684
β-cell glucose, 270P
β_1-adrenoceptor, 92L
β_2-adrenoceptor agonist, 349, 243P
β_2-adrenoceptor antagonist, 244P
β_2-adrenoceptor blocking, 275P
β_2-microglobulin, 401
Baroreceptor function, 431
Baroreflex, 383, 115S
Baroreflex resetting, 211
Baroreflex sensitivity, 211
Benzodiazepine, 9
Benzodiazepine anxiolysis, 527P
Bilirubin displacement, 345
Binding sites, 233S
Bioavailability, 603, 549P
Blood pressure, 27, 144, 669, 681, 684, 252P, 55S, 135S
Body sway, 619
Bopindolol, 242P
Breast milk, 290P
Bromazepam, 9
Bronchoconstriction, 289S
Bronchodilator effect, 717L
Buccal glyceryl trinitrate, 245P
Buccal nitrate, 437
Bucindolol, 393, 659
Bufuralol, 243P
Bumetanide-induced diuresis, 544P
BW430C(lamotrigine), 285P, 286P, 287P

Caffeine, 61
Calcium, 213S, 221S, 233S, 275S
Calcium antagonist, 235, 293P, 7S, 55S, 67S, 125S, 158S, 247S, 289S
Calcium blockers, 187S
Calcium channel activators, 247S
Calcium channel blockers, 95S, 115S

Calcium channels, 233S
Calcium entry blockers, 107S
Calcium ionophore, 275S
Calcium ions, 255S
Cancer, 297P
Capillary blood, 597
Captopril, 90L, 91L, 262P, 263P
Carbachol, 1, 526P
Carbamazepine, 611
Cardiac function, 245P
Cardiac output, 93
Cardiac volume, 245P, 169S
Cardioselectivity, 537P
Cardiovascular effect, 7S
Celiprolol, 245P
Central actions, 283P
Cerebral oxygen tension, 67S
Cerebral vessels, 67S
CGP 15210 G, 81
Chemoreceptor agonist, 547P
Chemotherapy, 303P
Children, 703
Chinese, 144
Chloroquine, 425L
Choline theophyllinate, 89L
Cholinergic nerves, 475
Cholinesterase inhibitors, 526P
Cholinesterases, 302P
Chronic cor pulmonale, 248P
Chronic idiopathic urticaria, 639
Chronic obstructive lung disease,
Chronic stable angina, 177S, 195S
Cimetidine, 546P
Circadian variation, 718L, 719L
Cis-platinum, 426L
Cisapride, 475
Citric acid, 355
Clemastine, 377
Clinical study, 492
Clobazam, 9
Clonidine, 431, 542P
Clotting factor activity, 643
CNS depression, 304P
CNS effects, 286P
Codeine, 290P
Cold urticaria, 270P
Cold-induced pain model, 289P
Combination therapy, 130S
Concentration effect modelling, 55S
Concentration-response relationships, 417
Congestive heart failure, 263P
Contraction, 255S
Controlled release, 567P
Converting enzyme inhibition, 27
Cord serum, 345
Coronary
  artery disease, 675, 245P, 247P, 158S
  blood flow, 195S
  care, 539P
  haemodynamic effects, 247P
  spasm, 187S
  vascular resistance, 147S
Corticosteroids, 278P
Cortisol, 129, 414
Cotrimoxazole, 482
Creatinine clearance, 401
Cryopreserved hepatocytes, 546P
Cyclic AMP, 537P
Cytochrome P-450, 219

Deafness, 274P
Debrisoquine 4-hydroxylase, 67
Debrisoquine oxidation phenotyping, 254P
Debrisoquine, 81, 555
Dementia, 261P
Depressed patients, 528P
Depression, 411
Depressive patients, 261P
Desethylamiodarone, 307, 299P
Desethylamodiaquine, 307
Dexamethasone suppression test, 261P
Dextromethorphan, 290P
Dextropropoxyphene, 631
Diazepam, 111, 619, 286P, 290P
Diflunisal, 225
Digoxin, 281P
Dihydroergotoxine, 603
Dihydropyridine derivatives, 187S
3,4-dihydroxyphenylethylene glycol, 267P
Diltiazem, 447
Disodium cromoglycate, 41
Disopyramide, 453, 522P
Dithranol, 185
Diuretics, 95S
Domperidone, 268P, 284P
Dopamine, 269P
Dopamine antagonists, 339
Dopamine prodrug glutamyl dopa, 268P
Dopamine receptors, 339
Dose-response, 486, 675, 135S
Double product, 405
Double-blind studies, 428L
Doxazosin, 251P
Doxepin, 497
Drug interaction, 219, 707
Drug metabolism, 219
Drug oxidation, 482
Drug serum binding, 85
Dyskinetic-dystonic reactions, 258P

Edrophonium, 255P
Effective renal plasma flow, 101
Efficacy, 111, 119, 327, 575, 567P, 125S, 139S
Emesis control, 426L
Enalapril, 211, 262P, 263P, 279P, 280P
Enalapril chronic dose, 264P
Enalapril effects, 263P
Endoscopy, 527P
Endothelium dependent, 276P
Enoxacin, 583
Environmental factors, 500
Enzyme induction, 129
Epileptics, 285P, 287P
2,3-epoxide, 643
Equilibrium dialysis, 85
Erythrocytes, 148
Essential hypertension, 93, 279P, 107S, 125S, 130S, 135S
Essential tremor, 244P
Ethacrynic acid, 259P

Ethanol, 631, 684, 267P
Ethoxyresorufin *O*-deethylation, 302P
7-ethoxycoumarin, 77
Excitation-contraction coupling, 255S
Exercise, 144, 405
Exercise capacity, 158S
Exercise testing, 177S
Exercise-induced ischaemia, 169S
Extraction solvents, 293P
Eye movements, 619

Family studies, 555
Felodipine, 383, 249P, 250P, 299P
(+)-fenfluramine, 549P
Fibreoptic bronchoscopy, 180L
First dose effect, 535P
Flecainide, 333, 522P
Flestolol, 691
Fluorescent indicators, 221S
Flurbiprofen, 511

Ganglia, 281S
Gastric acid secretion, 133
Gastric emptying, 339
Gastric secretion, 137
Gastrointestinal haemorrhage, 699
Gastrointestinal smooth muscle, 293P
General practice, 273P
Genetic factors, 500
Genetic hydroxylation, 81
Genetic linkage, 67
Geriatrics, 298P
Glucagon 1-21 peptide, 271P
Glucagon, 271P
Glucose intolerance, 529P
Glucose-clamp technique, 270P
Glyceryl trinitrate, 246P
Gout, 511
Growth hormone, 649
Guanethidine, 535P
Guanfacine, 649
Guar, 544P
Gut flora, 545P

H_2 breath test, 294P, 479
H_2-receptor antagonists, 133, 710
[^{3}H]-5-HT uptake, 292P
HOE 498, 27
Haemodialysis, 155
Haemodynamic, 437, 675, 524P, 163S
Half-life, 174
Health status, 272P
Heart failure, 263P
Heart rate, 17, 684, 55S
Heparin therapy, 266P
Hepatic enzyme induction, 301P
Hexamethonium, 1
Histamine, 377, 486, 270P, 554P, 267S
Histamine (H_1-receptor) antagonism, 283P
Histaminergic mechanism, 283P
Human
  colon, 475
  liver, 67
  milk, 497
  skin, 185, 377
Hydralazine, 276P, 524P
Hydroxy metabolite, 411
12-hydroxyeicosatetraenoic acid, 185
5-hydroxytryptamine, 37
Hypercapnia, 631
Hyperglycaemia, 529P
Hypertension, 37, 140, 205, 387, 393, 401, 252P, 263P, 275P, 280P, 524P, 536P, 62S, 115S, 120S, 139S
Hypnotic activity, 256P

ICI 118551, 244P
Idazoxan, 649
Imidazo-pyridine (SL 80-0750), 257P
Imipramine binding, 259P, 528P
Indomethacin, 252P
Indoprofen, 463
Inflammatory bowel disease, 532P
Inflammatory cells, 521P
Influenza vaccination, 47
Inhibition of metabolism, 313
Inotropic state, 147S
Insulin secretion, 75S
Interaction, 225, 238
Interictal electroencephalographic spikes, 287P
Interleukin-2, 107
Intra-arterial blood pressure, 140
Intra-ocular pressure, 535P
Intracranial pressure, 67S
Intrarenal sodium handling, 88S
Intrinsic sympathomimetic activity, 92L, 242P
Invasive monitoring, 163S
Ipratropium bromide, 41
Ischaemic heart disease, 269P, 524P
Isoniazid, 323
Isoprenaline, 684
Isosorbide-5-mononitrate, 540P, 541P
Isoxicam, 533P

Kallikrein, 197
Ketanserin, 37, 525P, 535P
6-keto-PGE_1, 681
Ketoconazole, 163
Ketoprofen, 567, 298P, 549P
Kidney function, 197
Koe 3290, 537P

L-643,441, 133
L-714,465, 459
LA propranolol, 144
Lactulose, 479
Lamotrigine (BW430C), 285P, 286P, 287P
Left ventricular afterload reduction, 169S
Left ventricular function, 158S
Lesch-Nyhan syndrome, 489
Leukotriene D_4, 554P
Leukotrienes, 518P
Li 32-468, 275P
Lignocaine, 170, 421, 695, 180L, 521P, 539P, 695
Lipid peroxidation, 148
Lisinopril, 281
Lithium, 259P
Liver, 302P, 303P
Liver and renal blood flow, 235
Liver microsomes, 77, 531P
Long-acting metoprolol, 387
Long-acting pinacidil, 140
Loprazolam, 119

Lorazepam, 9
Lower respiratory tract infections, 583
Lymphocytes, 277P, 278P, 537P
Lymphocytic [^{3}H]-oubain binding, 259P

MAO Type A inhibition, 266P
Mast cells, 221S, 267S
Mefenamic acid, 254P
Mefloquine, 469
Mental function, 305P
Menthol, 293P
Meptazinol, 631
Metabolism, 55, 555, 23S
Methotrexate, 297P
Methoxamine, 41
3-methoxy-4-hydroxyphenylglycol, 541P, 542P
Metoclopramide, 426L, 258P, 296P, 297P
Metoprolol, 205, 245, 387, 555, 524P
Microcomputer system, 304P
Midalcipran F 2207, 291P, 292P
Midazolam, 492, 256P, 534P
Mixed lymphocyte reaction, 107, 489
Monoamine metabolites in CSF, 492
Motility modifiers, 479
Motor nerves, 281S
Mucin, 275S
Mucociliary clearance, 688
Muscle spindles, 369
Myocardial
  infarction, 522P, 29S
  ischaemia, 195S
  metabolism, 147S
  oxygen demand, 195S
Myogenic response, 383

Nadolol, 93, 401
Naloxone, 262P
Narcotic analgesics, 553P
N-desmethylodoxepin, 497
Neostigmine, 255P
Neurotransmission, 281S
Neurotransmitter release (synaptosome), 221S
Neutrophil, 523P
Nicardipine, 524P, 7S, 23S, 29S, 55S, 62S, 67S, 75S, 84S, 88S, 95S, 99S, 120S, 125S, 130S, 135S, 139S, 147S, 158S, 163S, 169S, 177S, 178S, 195S
NIDDM patients, 271P
Nifedipine, 152, 155, 248P, 524P, 550P
Nisoldipine, 152, 191, 235, 675
Nitrazepam, 361
Nitrendipine, 152
Nizatidine, 710
Non-alcoholic heavy drinkers, 529P
Noradrenaline, 649, 669, 266P, 267P
Normal volunteers, 619
Normotensive volunteers, 211
Norpethidine, 55
Nortriptyline, 411
NSAIDs, 567

Obesity, 61
Obstructive coronary artery disease, 169S
Omeprazole, 137
Opiate, 283P
Oral contraceptive steroids, 288P
Oral–caecal transit time, 425L
Oruvail, 549P
[^{3}H]-oubain binding, 277P, 278P
Oxazepam, 225
Oxidation polymorphism, 67
Oxidative drug metabolism, 710
Oxprenolol, 393
Oxyfedrine, 405

Paracetamol, 174, 548P
Parasympathetic effect, 17
Parkinson's disease, 284P
Paroxetine, 282P
Particle deposition, 688
Partial agonist activity, 417, 538P
Parturition, 256P
Penicillin, 345
Peptides, 519P
Percutaneous absorption, 421
Peripheral blood flow, 447
Pethidine, 55
Pethidine disposition, 531P
PGE_2, 355
$PGF_{2\alpha}$, 355
pH calcium, 221S
pH lability, 85
Pharmacodynamics
  captopril, 90L, 91L
  doxazosin, 251P
  loprazolam, 119
Pharmacokinetics, 55, 61, 225, 307, 323, 327, 469, 575, 611, 691, 699, 703, 286P
Pharmacokinetics
  diltiazem, 447
  disopyramide, 453
  doxazosin, 251P
  flecainide, 333
  loprazolam, 119
  nicardipine, 23S
  nifedipine, 155
  omeprazole, 137
  ranitidine, 166
  tryptophan, 317
  verapamil, 101
Phenacetin *O*-deethylase, 67
Phenotyping, 254P
Phenylbutazone, 511
Phenytoin, 238, 323, 611, 619, 286P
Pindolol, 205, 417, 659, 537P
Pituitary hormone release, 84S
Placebo, 552P, 178S
Plasma concentrations, 111, 619, 714
Plasma levels, 163S
Plasma potassium, 243P
Plasma renin activity, 120S
Plasma cortisol, 163
Platelet [^{3}H]-clonidine binding, 261P
Platelet aggregation, 681, 543P
Platelets, 191
Polymorphism, 81, 555
Population studies, 555
Post-mortem brains, 260P
Posturography, 9
Potassium, 148, 259P
Potential-dependent channels (PDC), 312S

Prazosin, 524P
Prednisolone, 159, 414
Pregnant women, 256P
Presynaptic adrenoceptors, 649
Primary biliary cirrhosis, 77
Primary hypertension, 144
Prochlorperazine, 258P
Propofol, 529P
Propranolol, 219, 401, 417, 659, 251P, 536P, 548P
Prostaglandin D_2, 185, 270P, 518P
Protein binding, 111, 159, 411, 695
Psychomotor performance, 9, 361, 305P
Pupil size, 535P

Quinolone, 583
QTc interval, 507
Quadriplegia, 166

Radial artery, 276P
Ranitidine, 55, 166, 170, 377, 699, 546P
Receptor-operated channels (ROC), 213S
Red cell filterability, 152
Relaxation, 255S
Renal
  blood flow, 93
  disease, 297P
  function, 268P, 280P
  impairment, 264P
  transplantation, 159
Renin, 681
Renin-angiotensin, 27
Reproterol, 349
Respiration, 503
Rest angina, 187S
Retard formulations, 603
Rifampicin, 323
Rubidium-86, 278P

Sabidal SR 270, 89L
Saccadic eye movements, 631, 304P
Salbutamol aerosol, 717L
Salicylate pharmacokinetics, 551P
Schistosomiasis, 313
Schizophrenic patients, 260P
Serum concentrations, 597
Serum potassium, 521P
Side effects, 140, 278P
Single-dose effect, 393
  studies, 285P
Skin, 283P
Sleeping heart rate, 538P
Small and large arteries, 107S
Smoking, 453
Smooth muscle, 213S, 255S
Sodium excretion, 197
  valproate, 288P
(+)-sotalol, 507
(±)-sotalol, 507
Sparteine metabolism, 531P
Spironolactone, 536P
Stable angina, 178S
Stereochemistry, 463
Stereoselective disposition, 463
Steroids, 288P
Stimulated growth hormone, 283P
Stimulus-secretion coupling, 267S
Sucralfate, 238
Sucralfate–warfarin interaction, 178L
Suicide victims, 259P
Sulindac 252P, 545P
Sulphamethoxazole, 482, 575P
Sulphonamide, 345
Superoxide, 148
Surgery, 174
Sustained-release formulations, 589
Sweat glands, 1, 526P
Syringe driver, 515L
Systemic coronary haemodynamic effects, 247P
Systolic time intervals, 55S

Temazepam, 361
Terfenadine, 639, 283P
Terminal care, 515L
Theophylline, 47, 219, 589, 300P, 545P
Theophylline interaction, 583
Theophylline 'trough' serum concentrations, 718L, 719L
Therapy adherence, 714
Thromboxane receptor blocking drug, 543P
Thymoxamine, 535P
Tilt test, 140
Timolol, 459
Tobramycin, 597
Tofisopam, 492
Tolbutamide, 482, 270P
Tolerability, 139S
Total parenteral nutrition, 253P
Tracking, 619
Treadmill exercise, 178S
Treatment
  predictability, 428L
  responses, 530P
Tremor, 369, 431
Tricyclic antidepressants, 293P
Trimazosin, 533P
Trimethoprim, 482, 575
Tryptophan, 317
t-tubule membranes, 233S
Tuberculous, 303P
Tulobuterol aerosol, 717L
(+)-tubocurarine, 1
Tussives, 355
Tyramine, 266P

Ultrasound, 421
Ultraviolet-B, 185
Urinary pH, 333
Urine, 545P
Urticaria, 486

Vasodilation, 383, 62S, 147S
Venous blood, 597
Ventricular volume, 437
Verapamil, 101, 191, 62S
Verapamil cardiovascular effects, 251P
Verapamil kinetics, 251P
Vitamin D, 303P
Vitamin K_1, 643, 265P, 301P
[^{125}I]VIP binding, 260P
Volunteers, 75S, 84S

Warfarin, 643, 707
  dosage, 177L
  response, 300P
Welsh Adverse Drug Reaction Scheme, 272P

Zopiclone excretion, 290P